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Introduction {#sec006}
============

Globally, Tuberculosis (TB) remains a major public health concern with an estimated 10 million incident TB patients and 1.6 million deaths due to the disease in 2017.\[[@pone.0230848.ref001]\] In recent years, drug-resistant TB (DR-TB) has emerged globally. Drug-resistant TB is posing an additional threat to TB control efforts due to the complexity of its treatment and poor treatment outcomes. The World Health Organization (WHO) estimated that there were about 558,000 incident multidrug-resistant TB or rifampicin-resistant TB (MDR/RR-TB) patients globally in the year 2017, but only 29% were notified. The WHO also estimated that 3.5% of new TB cases and 18% of previously treated TB patients had MDR/RR-TB in 2017.\[[@pone.0230848.ref001]\]

In 2000, WHO recommended the 20--24 month standardized second-line drug (SLDs) regimens for the treatment of MDR/RR-TB patients in resource-limited settings.\[[@pone.0230848.ref002]\] The WHO also set a target of achieving a 75--90% treatment success rate (i.e., cured or treatment completed) by 2015.\[[@pone.0230848.ref003]\] However, the 2018 global TB report shows that only 55% of patients initiated on MDR/RR-TB treatment during the year 2015 had successful treatment outcomes.\[[@pone.0230848.ref001]\] A recent systematic review in 2017 reported successful treatment outcomes among MDR/RR-TB patients on standardized SLD regimen to be 64%. The studies included in the review were mostly from countries with low HIV coinfection and thus, recommended for systematic assessment of treatment outcomes in high HIV coinfection countries of sub-Saharan Africa.\[[@pone.0230848.ref004]\]

Treatment of MDR/RR-TB is not only longer, more complex and expensive but also involves the use of drug regimens that are more toxic and could lead to severe side effects, such as deafness and liver damage.\[[@pone.0230848.ref005],[@pone.0230848.ref006]\] Though, recently WHO recommended shorter regimens for management of MDR/RR-TB\[[@pone.0230848.ref014]\], low-middle income countries still largely use longer standardized SLD regimens requiring patients to consume drugs for not less than eighteen months.

Studies conducted in various countries suggest that MDR/RR-TB treatment outcomes vary by factors specific to individual patients and are also related to TB program implementation.\[[@pone.0230848.ref007]--[@pone.0230848.ref010]\] Patient-level characteristics like HIV-coinfection, alcohol and substance use, smoking and low body mass index have been found to be associated with unsuccessful treatment outcomes. Programmatic characteristics like delay in treatment initiation, duration of treatment, type of drug sensitivity testing, individualized treatment regimens and use of directly observed therapy have also been found to be associated with adverse MDR/RR-TB treatment outcomes.\[[@pone.0230848.ref007]--[@pone.0230848.ref010]\]

Zimbabwe, which is located in southern Africa, is among the 14 high burden countries (HBCs) with a triple burden of TB, TB/HIV and MDR-TB.\[[@pone.0230848.ref001]\] In Zimbabwe, there were an estimated 37,000 incident TB patients and 8,300 TB-associated deaths in 2017.\[[@pone.0230848.ref001]\] In the same year, there were an estimated 1,300 MDR/RR-TB patients in the country with a prevalence of 4.6% and 14% among new and previously treated TB patients, respectively.\[[@pone.0230848.ref001]\] In 2010, the National TB Programme (NTP) of Zimbabwe released the "Programmatic Management of Drug-Resistant TB" (PMDT) guidelines with the use of standardized SLDs for twenty months.\[[@pone.0230848.ref011]\] In 2016, the 9--11 month injectable-based short treatment regimen was adopted as a pilot but in only one of the country's districts, which was supported by a non-governmental organisation. This has been however rolled out by the NTP in some of the districts in Zimbabwe

In 2017, WHO estimated that less than 40% of the MDR/RR-TB patients were diagnosed and put on treatment in Zimbabwe.\[[@pone.0230848.ref012]\] Also, among those initiated on treatment, more than 50% had unsuccessful treatment outcomes. High unsuccessful treatment outcomes in Zimbabwe are largely due to the fact that treatment outcomes of about 32% are missed during routine reporting and are eventually considered as 'unsuccessful' treatment outcomes.\[[@pone.0230848.ref012]\] There has been no systematic assessment of treatment outcomes of MDR/RR-TB patients treated under the Zimbabwe NTP, nor has there been assessment of the individual and programmatic characteristics associated with unsuccessful treatment outcomes. Knowledge of factors affecting outcomes among MDR/RR-TB patients can guide the NTP to make informed decisions on policies and strategies aimed at improving treatment outcomes for subsequent MDR/RR-TB patient cohorts. We therefore conducted a study aimed at assessing the profile, treatment outcomes and factors associated with unfavourable treatment outcomes among patients initiated on MDR/RR-TB treatment under the Zimbabwe NTP between 2010 and 2015.

Methods {#sec007}
=======

Study design {#sec008}
------------

This was a cohort study using secondary data routinely collected from fifty-two out of sixty-three district hospitals and thirty out of thirty-five Urban Poly-clinics in the two metropolitan provinces within the Zimbabwe NTP.

General setting {#sec009}
---------------

Zimbabwe is a landlocked country with an estimated population of 17 million.\[[@pone.0230848.ref001]\] The country has 62 districts, which are further grouped into ten provinces of which two are Metropolitan provinces (Harare, the capital city and Bulawayo, the second-largest city). The country's public healthcare referral system constitutes four levels: 1) the quaternary level constituting six central hospitals located in the two metropolitan provinces 2) the tertiary level consisting eight provincial hospitals which are the highest referral hospitals providing selected basic medical specialties for the eight rural provinces 3) the secondary level constituting at least one district and or general hospital per district and last 4) the primary care level consisting of rural and urban healthcare facilities that provide primary health care services.

### Specific setting {#sec010}

*Diagnosis of MDR/RR-TB*. In Zimbabwe, TB diagnosis and treatment services are provided in public healthcare facilities and are integrated with general health services. Private laboratories complement efforts of public healthcare by providing TB diagnosis services for patients seeking care in private sector. Before 2013, only previously-treated sputum positive pulmonary tuberculosis patients (PTB) and MDR-TB contacts were considered as presumptive MDR-TB patients and evaluated for MDR-TB. Their sputum specimens were subjected to phenotypic culture and drug susceptibility testing (CDST) with BBL^TM^ MGIT^TM^ Mycobacterial Growth Indicator Tubes Becton Dickinson, Sparks, MD or genotypic Mico-bacterium Tuberculosis Rifampicin-resistant (MTB/Rif) assay. From 2013 onwards, Xpert MTB/Rif assay was used upfront for diagnosis of TB and rifampicin resistance in MDR-TB high-risk groups (retreatment TB patients, chest symptomatic MDR-TB contacts, those HIV-positive, health workers with pulmonary TB miners with PTB and children \<5 years). In all RR-TB patients, the remainder of the two collected sputum specimens is sent to one of the country's two national reference laboratories for CDST in order to assess drug susceptibility to all the first-line drugs.\[[@pone.0230848.ref011]\]

*Treatment initiation and follow-up MDR/RR-TB*. All diagnosed MDR/RR-TB patients are registered and started on treatment at either district or provincial hospitals or at polyclinics and infectious disease hospitals in metropolitan provinces. The District Medical Officer is responsible for providing oversight on the clinical management of all MDR/RR-TB patients in their respective districts.

On registration at the district hospital, the patient is notified to the NTP and a patient-held DR-TB treatment card is issued. Simultaneously, the socio-demographic and clinical details of the patient are documented in the Daily Observed Treatment (DOT) DR-TB register maintained at health facility. The patient follow-up visit details are updated regularly in the 'DOT DR-TB' by the healthcare workers. Patient data in the health facility 'DOT DR-TB' register are also entered into the DR-TB register which is maintained and updated by DR-TB co-ordinators at district level.

As part of pre-treatment evaluation for all patients, laboratory investigations like liver function tests, renal function tests and complete blood count are supposed to be done before initiation of treatment. The district clinical management team initiates treatment based on pre-treatment evaluation. Details of the clinical and laboratory examinations are documented in the DR-TB card and also in the clinical notes attached to the DR-TB card. During the study period, the WHO recommended use of a standardised DOTS-Plus regimen for the management of MDR/RR-TB patients.\[[@pone.0230848.ref013],[@pone.0230848.ref014]\] The duration of treatment was at least 20 months with a minimum of six months (and four months after culture conversion) in the intensive phase and 14 months of the continuation phase. Oral drugs, namely levofloxacin, pyrazinamide, cycloserine and ethambutol were given both during the intensive and continuation phases. The injectable kanamycin was provided six days a week during the intensive phase. Treatment dosages were dispensed based on patient weight.

After treatment initiation, patients are monitored for two weeks at facilities where treatment is initiated before considering if the patient is stable and tolerating the regimen. Those considered "Stable" were patients who were able to ingest medication, did not show signs of adverse drug reaction and had all the laboratory investigations within normal limits. Based on clinical severity and distance of travel from the patient's residence (\>10 km), patients are either admitted and monitored or asked to visit the district hospital daily. After two weeks, based on proximity to a health facility, patients either continue DOTS-Plus in district hospitals or they are referred to primary health facilities nearest to their residence. Patients are followed-up as per PMDT guidelines and the programmatic treatment outcomes are ascertained by the medical officer (**[Table 1](#pone.0230848.t001){ref-type="table"}**). If a patient developed side-effects due to kanamycin, their dosage was reduced; however, currently, they are switched to capreomycin.\[[@pone.0230848.ref011]\]

10.1371/journal.pone.0230848.t001

###### Treatment outcome definitions.

![](pone.0230848.t001){#pone.0230848.t001g}

  TREATMENT OUTCOME            Definition
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment completed          -A patient who has completed treatment but who does not have a negative sputum smear or culture result in the last month of treatment and on at least one previous occasion. The sputum-smear or culture may not have been done or the results are not available.
  Cure                         A patient whose sputum smear or culture was positive at the beginning of treatment and who was sputum smear or culture-negative in the last month of treatment and on at least one previous occasion.
  Treatment success            The sum of patients who were initially sputum smear or culture positive and were cured and those who completed treatment.
  Treatment Failure            Patient who is sputum smear or culture-positive at 5 months or later during treatment. Patient who was initially smear-negative before starting treatment and became smear-positive after completing the intensive phase of treatment. Any patient who is found to have MDR-TB at any point of time during the treatment, whether they are smear negative or -positive
  Died                         Patient who dies for any reason during the course of treatment
  Default/ Lost to Follow-up   Patient whose treatment was interrupted for two consecutive months or more
  Transfer out                 Patient who has been transferred to another recording and reporting unit and for whom the treatment outcome is not Known.
  Not evaluated                Patient whose treatment outcomes are not ascertained

\-

Source: Ministry of Health and Child Care. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis in Zimbabwe. Harare, Zimbabwe; 2014.

Patients are also offered provider-initiated HIV testing services in the MDR-TB pre-treatment phase and those found to be HIV positive are assessed for initiation on antiretroviral therapy (ART).and also Cotrimoxazole preventive therapy (CPT) as per WHO guidelines. As per the national guidelines in use during the study period, they were initiated on a fixed-dose combination once-daily pill of Tenofovir v plus(+) Lamuvidine (or Emtricitabine) plus (+) Efavirenz (TDF+3TC (or FTC)+EFV) as the preferred first-line ART regimen among adult PLHIV. In children living with HIV abacavir+lamuvidine+efavirenz (or Lopinavir/Ritonavir) (ABC + 3TC + EFV (or LPV/r)) was the preferred first-line ART regimen.\[[@pone.0230848.ref015]\]

### Study population {#sec011}

All MDR/RR-TB patients initiated on treatment between 2010 and 2015 under the Zimbabwe NTP and continued their treatment at either district hospitals or urban polyclinics were included in the study. Those patients who were referred back to primary health facilities for DOTS-Plus treatment were excluded due to resource and time constraints in travelling to all primary healthcare facilities to collect their socio-demographic and clinical details.

### Data variables, sources of data and data collection {#sec012}

Patient demographic and clinical data were extracted from the health facility DOT register, individual patient clinical notes and the district DR-TB register using a structured proforma. Data extraction was done by District TB coordinators of the respective districts following training by the principal investigator. A data extraction manual was also shared by the principal investigator indicating the source of variables and explaining the standard procedure to be followed while extracting each variable. District Environmental Health Officers (DEHOs) of the respective districts also crosschecked the source registers and validated 10% of the extracted data. Data was extracted from August to December 2018.

*Operational definitions*:

*Duration from diagnosis to treatment initiation*: The number of days between the diagnosis date of rifampicin resistance to date of initiating standardised SLDs for management of MDR/RR-TB.

*Severe Adverse Events (SAEs)*: All the adverse events as listed in PMDT guidelines of Zimbabwe.\[[@pone.0230848.ref011]\]

*Other comorbidities*: All the self-reported comorbidities (except for HIV) recorded during the initiation of treatment.

Data entry, analysis and reporting {#sec013}
----------------------------------

Data were double entered and validated using EpiData Entry software (EpiData Association, Odense, Denmark). Data were analysed using EpiData analysis (version 2.2.2.182, EpiData Association, Odense, Denmark) and Stata (version 12.0 STATA Corp., College, TX, USA). Study findings were reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.\[[@pone.0230848.ref016]\]

Categorical variables such as MDR/RR-TB treatment outcomes were summarized using numbers and percentages while medians (interquartile range (IQR)) were calculated for skewed continuous data such as age and weight at treatment initiation.

The TB treatment outcomes were ascertained at completion of treatment unless there was a known outcome such as deaths, LTFUs or treatment failure. Those classified as LTFU were defined as patients whose MDR-TB treatment was interrupted for two or more consecutive months for any reason. All treatment outcomes were defined in line with WHO guidelines. The primary outcome, "unfavorable outcome" was comprised of 'death', 'loss to follow-up' (LTFU), 'failure' and 'not evaluated' while 'cured' and 'treatment completed' comprised 'favorable outcome' in line with recent meta-analysis and systematic reviews on MDR-TB treatment outcomes.\[[@pone.0230848.ref004],[@pone.0230848.ref009]\]

To assess factors associated with "unfavorable outcome", we used univariate and multivariate generalized linear model with a log-link and binomial distribution or alternatively a Poisson distribution with robust error variances, as the binomial model failed to converge. All potential factors with a p≤0.25 in the unadjusted model were included in the multivariate regression model. Unadjusted and multivariate-adjusted relative risks with 95% confidence interval (CI) were calculated as a measure of association. A 𝑝 value\< 0.05 was considered statistically significant.

Ethics approval {#sec014}
---------------

Ethics approval was granted by The Union Ethics Advisory Group of the International Union against Tuberculosis and Lung Diseases, Paris, France, IRB number EAG 53/18 and the Medical Research Council of Zimbabwe (MRCZ), IRB number MRCZ/A/2331 Permission to access data was granted from the Ministry of Health and Child Care. No patient consent was required as this was already granted by the Ministry of health and child care on behalf of the patients since this was a retrospective study. Data were fully anonymised as only DR-TB registration numbers were abstracted onto data collection proformas as unique patient identifiers. The Ethics committee waived the requirement for individual informed consent.

Results {#sec015}
=======

Of the total 935 MDR/RR-TB patients initiated on treated during the study reference period, 473 (51%) were followed up at district hospitals and urban healthcare facilities and were included in the study. The 473 patients in our study contributed 672.5 person-years of follow-up time. The median age of these 473 participants was 34 (IQR, 29--42) years and 230 (49%) were males. The demographic details of the participants are shown in **[Table 2](#pone.0230848.t002){ref-type="table"}**.

10.1371/journal.pone.0230848.t002

###### Baseline demographic characteristics of MDR/RR-TB patients initiated on treatment during 2010 to 2015 in Zimbabwe.
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  Characteristic       N (%)
  -------------------- ---------------
  **Total**            473 (100)
  Sex                   
      Male             230 (48.6)
      Female           241 (51.0)
      Missing          2 (\<1)
  Age                   
      \<5              2 (\<1)
      5--14            10 (2.1)
      15--24           56 (11.8)
      25--34           169 (35.7)
      35--44           149 (31.5)
      45--54           47 (9.9)
      55+              34 (7.2)
      Not recorded     6 (1.3)
      *Median (IQR)*   *34 (29--42)*
  Marital status        
      Married          202 (42.7)
      Single           143 (30.2)
      Widowed          44 (9.3)
      Divorced         25 (5.3)
      Missing          59 (12.5)

MDR-TB = multidrug resistant tuberculosis; RR-TB = rifampicin resistant tuberculosis; IQR = interquartile range

**[Table 3](#pone.0230848.t003){ref-type="table"}**shows the clinical characteristics of the study participants. Of all patients, 257 (54%) were new TB patients, followed by 116 (25%) with 'retreatment after failure'. Of the 352 (74%) study participants co-infected with HIV, 321 (91%) were on ART and 323 (91%) received CPT. The majority of the HIV-positive and ART naïve, and with unknown HIV status were new TB patients. Of the 473 participants, 402 (85%) were diagnosed with a genotypic test and 290 (68%) were initiated on MDR-TB treatment within seven days of MDR/RR-TB diagnosis while it was more than four weeks in 64 (14%) of the participants. Overall, the median duration from diagnosis to initiation of MDR/RR-TB treatment was 1 (IQR, 0--13) days.

10.1371/journal.pone.0230848.t003

###### Clinical characteristics of MDR/RR-TB patients at baseline and/or during MDR-TB initiated on treatment in Zimbabwe, 2010--2015.
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  Characteristic                                      N              (%)       
  --------------------------------------------------- -------------- --------- -----------
  **Total**                                           ** **          **473**   **(100)**
  *Type of TB*                                        New            257       (54.3)
  Retreatment After LTFU                              19             (4.0)     
  Retreatment After Failure                           116            (24.5)    
  Retreatment Relapse                                 81             (17.1)    
  *Duration from diagnosis to treatment initiation*   ≤7 days        290       (61.3)
  8--30 days                                          71             (15.0)    
  31--90 days                                         32             (6.8)     
  \>90 days                                           32             (6.8)     
  Not recorded                                        48             (10.2)    
  *Type of TB diagnostic test*                        Genotypic      402       (85.0)
  Phenotypic                                          53             (11.2)    
  *Baseline CDST of Isoniazid*                        Sensitive      35        (7.4)
  Resistant                                           172            (36.4)    
  Not recorded                                        266            (56.2)    
  *Baseline CDST of Ethambutol*                       Sensitive      104       (22.0)
  Resistant                                           65             (13.7)    
  Not recorded                                        304            (64.3)    
  *Baseline CDST of Streptomycin*                     Sensitive      99        (20.9)
  Resistant                                           66             (14.0)    
  Not recorded                                        308            (65.1)    
  *HIV status*                                        HIV negative   101       (21.4)
  HIV-positive                                        352            (74.4)    
  Untested/unknown                                    20             (4.3)     
  *ART status (n = 352)*                              Yes            321       (91.2)
  No                                                  18             (5.1)     
  Not recorded                                        13             (3.7)     
  *CPT status (n = 352)*                              Yes            323       (91.8)
  No                                                  11             (3.1)     
  Not recorded                                        18             (5.1)     
  *Encountered SAE during treatment*                  Yes            118       \(25\)
  No                                                  324            (68.5)    
  Not recorded                                        36             (7.6)     
  *Other comorbidities*                               Yes            17        (3.6)
  No                                                  456            (96.4)    

TB = Tuberculosis; MDR-TB = Multi drug Resistant TB; RR-TB = Rifampicin Resistant TB; DST = Drug sensitivity pattern; LTFU = Loss to follow-up; IQR = interquartile range; ART = Anti-retroviral treatment; CPT = cotrimoxazole prophylactic treatment; SAE = Serious Adverse events;

Overall, 17 (4%) patients had a documented comorbidity other than HIV. These 17 had different comorbidities with the most common being, 3/17 (18%) anaemia, 2/17 (12%) diabetes mellitus, and 2/17 (12%) renal failure. Among all the participants, 118 (25%) developed SAEs during treatment. Among those with SAEs, 80 (68%) had hearing disorders/impairments, 14 (12%) had psychosis, 9 (8%) had jaundice,8 (7%) had Steven Johnson syndrome and another 8(7%) had nausea, diarrhoea and vomiting (**[Table 4](#pone.0230848.t004){ref-type="table"}**).

10.1371/journal.pone.0230848.t004

###### Distribution and type of severe adverse events encountered during MDR-TB treatment among MDR/RR-TB patients in Zimbabwe, 2010--2015.
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  Severe Adverse Events           N     n    (%)
  ------------------------------- ----- ---- --------
  hearing disorder/impairment     118   80   (67.8)
  psychosis                       118   14   (11.9)
  jaundice                        118   9    (7.6)
  Steven Johnson Syndrome         118   8    (6.8)
  nausea, diarrhoea & vomitting   118   8    (6.8)
  seizures                        118   4    (3.4)
  peripheral nueropathy           118   3    (2.5)
  severe chest pains              118   1    (0.8)
  blurred vision                  118   1    (0.8)
  Not recorded                    118   1    (0.8)

\*Patients may have presented with ≥1 severe adverse events hence percentages

do not add up to 100%.

The data on culture conversion and MDR-TB treatment outcomes among study participants are shown in **[Table 5](#pone.0230848.t005){ref-type="table"}**. Of the 287 (61%) participants with recorded culture conversion results, 259 (90%) had culture conversion within six months of treatment initiation. Of all patients, 184 (39%), (95% CI: 34.5--44.5) patients had an 'unfavourable' treatment outcome of whom 125 (26%) died while 39 (8%) were lost to follow-up. The proportion with an unfavourable treatment outcome (death, Treatment failure, LTFU and Not evaluated) increased annually from 0% in 2010 to 45% in 2015 (**[Fig 1](#pone.0230848.g001){ref-type="fig"}**).

![Treatment outcomes among MDR/RR TB patients registered in Zimbabwe between 2010 and 2015, stratified by year of treatment commencement.](pone.0230848.g001){#pone.0230848.g001}

10.1371/journal.pone.0230848.t005

###### Programmatic treatment outcomes of MDR/RR-TB patients initiated on treatment during 2010 to 2015 in Zimbabwe.
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  Treatment outcomes                                                    N (%)
  --------------------------------------------------------------------- ------------
  Total                                                                 473(100)
  **Culture conversion period**                                          
      ≤ 6 months                                                        259 (54.8)
      \>6 months                                                        28 (5.9)
      Not recorded                                                      186 (39.3)
  **End of TB treatment outcomes**                                       
      *Favourable outcomes*[^*a*^](#t005fn003){ref-type="table-fn"}     289 (61.1)
          Treatment completed                                           149 (31.5)
          Cured                                                         140 (29.6)
      *Unfavourable outcomes*[^*b*^](#t005fn004){ref-type="table-fn"}   184 (38.9)
          Died                                                          125 (26.4)
          LTFU                                                          39 (8.2)
          Failed                                                        4 (0.8)
          Not evaluated                                                 16 (3.4)

TB = Tuberculosis; MDR-TB = Multi drug Resistant TB; RR-TB = Rifampicin Resistant TB;

LTFU = loss to follow up

*a--*favourable outcomes is a combination of those who completed treatment and who were cured

*b--*adverse outcomes is a combination of those who died, where LTFU, failures and not evaluated

*NB*: Please note that the end of TB treatment outcomes do not add up to 100% because of rounding-off errors

Factors associated with an unfavourable outcome among patients on MDR-TB treatment are shown in **[Table 6](#pone.0230848.t006){ref-type="table"}**. Those who were HIV-positive and ART-naive (ARR = 2.60; 95% CI: 1.33--5.09) were more likely to have an unfavourable treatment outcome

10.1371/journal.pone.0230848.t006

###### Sociodemographic and clinical characteristics associated with unfavourable outcomes among MDR/RR-TB patients initiated on treatment during 2010 to 2015 in Zimbabwe.
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  Characteristic                                             No. on RR/MDR-TB treatment   Unfavourable     RR (95% CI)         ARR (95% CI)
  ---------------------------------------------------------- ---------------------------- ---------------- ------------------- -------------------
  **Total**                                                  **473**                      **184 (38.9)**                       
  Sex                                                                                                                          
      Male                                                   230                          92 (40.0)        Reference           Reference
      Female                                                 241                          92 (38.2)        0.95 (0.76--1.20)   1.01 (0.75--1.37)
      Not recorded                                           2                            0 (0.0)          \-                  \-
  Age                                                                                                                          
      \<24                                                   68                           21 (30.9)        Reference           Reference
      25--34                                                 169                          61 (36.1)        0.86 (0.57--1.29)   0.85 (0.51--1.43)
      35--44                                                 149                          57 (38.3)        1.06 (0.80--1.41)   1.03 (0.71--1.49)
      45--54+                                                47                           24 (51.1)        1.41 (1.00--2.00)   1.35 (0.83--2.19)
      55+                                                    34                           19 (55.9)        1.55 (1.08--2.22)   1.41 (0.83--2.4)
      Not recorded                                           6                            2 (33.3)         0.92 (0.29--2.91)   0.66 (0.15--2.78)
  Time from RR-TB diagnosis to MDR-TB treatment initiation                                                                     
      ≤7 days                                                290                          125 (43.1)       Reference           Reference
      8--30 days                                             71                           19 (26.8)        0.62 (0.41--0.93)   0.64 (0.39--1.06)
      31--90 days                                            32                           11 (34.4)        0.80 (0.49--1.31)   0.91 (0.48--1.72)
      \>90 days                                              32                           11 (34.4)        0.80 (0.49--1.31)   0.89 (0.47--1.67)
      Not recorded                                           48                           18 (37.5)        0.87 (0.59--1.28)   0.97 (0.56--1.66)
  Isoniazid DST pattern                                                                                                        
      Sensitive                                              35                           5 (14.3)         Reference           Reference
      Resistant                                              172                          54 (31.4)        2.20 (0.95--5.10)   2.12 (0.82--5.45)
      Not recorded                                           266                          125 (47.0)       3.29 (1.45--7.48)   2.69 (0.97--7.51)
  Ethambutol DST pattern                                                                                                       
      Sensitive                                              104                          32 (30.8)        Reference           Reference
      Resistant                                              65                           16 (24.6)        0.80 (0.48--1.34)   1.06 (0.52--2.16)
      Not recorded                                           304                          136 (44.7)       1.45 (1.06--1.99)   0.85 (0.33--2.15)
  Streptomycin DST pattern                                                                                                     
      Sensitive                                              99                           30 (30.3)        Reference           Reference
      Resistant                                              66                           14 (21.2)        0.70 (0.40--1.22)   0.74 (0.35--1.54)
      Not recorded                                           308                          140 (45.5)       1.50 (1.09--2.07)   1.33 (0.56--3.14)
  HIV & ART status                                                                                                             
      HIV-ve                                                 101                          27 (26.7)        Reference           Reference
      HIV+ve, on ART                                         321                          126 (39.3)       1.47 (1.03--2.08)   1.37 (0.89--2.11)
      HIV+ve, not on ART                                     18                           14 (77.8)        2.91 (1.94--4.37)   2.6 (1.33--5.09)
      HIV+ve, ART unknown                                    13                           8 (61.5)         2.3 (1.34--3.94)    2.07 (0.9--4.78)
      HIV status unknown                                     20                           9 (45.0)         1.68 (0.94--3.01)   1.87 (0.85--4.14)
  CPT status                                                                                                                   
      Yes                                                    323                          133 (41.2)       Reference           Reference
      No                                                     11                           6 (54.6)         0.82 (0.51--1.33)   \-
      Not recorded                                           18                           9 (50.0)         1.09 (0.54--2.22)   \-
  Other comorbidities recorded                                                                                                 
      Yes                                                    17                           10 (58.8)        0.65 (0.43--0.98)   0.64 (0.33--1.24)
      No                                                     456                          174 (38.2)       Reference           Reference

TB = Tuberculosis; MDR-TB = multi-drug resistant TB; RR-TB = rifampicin resistant TB; RR = relative risk; ARR = multivariate-adjusted relative risk; DST = drug sensitivity testing; ART = antiretroviral therapy; CPT = cotrimoxazole preventive therapy; SAE = severe adverse event

Discussion {#sec016}
==========

This was the first nationwide study in Zimbabwe to assess the profile, management and factors associated with unfavourable treatment outcomes of MDR/RR-TB patients. The key findings of the study, which are programmatically important, are listed here. 1) About three-quarters of the patients were co-infected with HIV; of them, one out of ten was not on ART. 2) About one-quarter of the patients developed SAEs and hearing impairment was the most common SAE. 3) Around six out of ten patients had favourable treatment outcomes and about one-quarter of the patients died during treatment. 4) One in seven patients encountered MDR-TB treatment delays following RR-TB diagnosis 5) Being co-infected with HIV but not being on ART was associated with having an unfavourable outcome.

This study had some strengths. First, this study included patients from all the districts spanning over five years since the country adopted standardized SLDs hence, the findings provide useful insights for follow-up programmatic decision making at national level. Second, the study was conducted under a routine programmatic setting, thus highlighting important operational challenges that are applicable to other NTPs in low-resource settings.

The study was not without limitations. First, the patients who were referred back to rural primary healthcare facilities for follow-up care after MDR-TB treatment initiation were not included. Compared to patients referred back, the patients included in our study were more likely to be from urban areas with better socio-economic status, education levels and access to healthcare services. Thus, the current study cohort is more likely to have had better treatment outcomes and higher treatment success rates. Second, there were missing data on key variables which include CDST results, socio-economic status, WHO clinical staging, CD4 cell count, timing of ART in relation to MDR-TB treatment commencement, nutritional status, MDR-TB drug regimens and their dosages, data on virological, immunological or clinical failure of patients initiated on ART and radiological findings of TB lesions--all which are important factors which may be related to MDR-TB treatment outcomes. Third, while comorbidities were recorded, these were determined during eliciting patient history at MDR-TB treatment initiation and were self-reported by patients, hence, there might have been an underestimation of prevailing comorbidities like diabetes mellitus, which require specific diagnostic tests. Fourth, details on management of SAEs such as changes in drug regimen or dosages and their effect on treatment outcomes were not assessed.

Though the overall treatment success rate from our study was lower than the 75--90% target recommended by WHO, this was higher than the 52% success rate with standardized regimens as reported in a recent meta-analysis.\[[@pone.0230848.ref017]\] The treatment success rate was also better than that reported in similar patient cohorts from South Africa\[[@pone.0230848.ref018],[@pone.0230848.ref019]\] and Zambia\[[@pone.0230848.ref020]\], where the majority of patients were co-infected with HIV. However, the better treatment outcomes in the current study may be due to potential selection bias of excluding patients treated at primary health centres. In contrast, better treatment success rates of around 75% have been observed in similar cohorts in Botswana and eSwatini with similar high HIV and MDR/RR-TB co-infection MDR/RR-TB cohorts.\[[@pone.0230848.ref021],[@pone.0230848.ref022]\] However, the patient in Botswana and eSwatini had received social support in the form of monetary incentives or nutritional and transportation support including psychological support at health facilities. No such social and psychological support mechanisms were made available in the current study setting and should be considered in the future for improving treatment outcomes.

Similar to previous studies, patients co-infected with HIV but not on ART had a higher risk of having unfavourable outcomes in particular death when compared to those who are HIV-negative.\[[@pone.0230848.ref023],[@pone.0230848.ref024]\] It is likely that such ART-naïve HIV co-infected patients were presenting with severe immunosuppression and hence denied the well-known benefits of life-saving ART in restoring their immune function.\[[@pone.0230848.ref021],[@pone.0230848.ref022]\] Thus, the finding highlights the importance of ART in limiting the unfavourable treatment outcomes among MDR/RR-TB patients in high HIV burden countries.

A quarter of patients in our study encountered SAEs during their treatment and similar findings were reported in a recent meta-analysis among MDR/RR-TB patients in high HIV burden countries. However, the percentages varied from 13% to 43% in various studies included in the review. The settings where individualised drug regimens were used had reported lower percentages of SAEs. Relatively, the high percentage of SAEs in our study setting may be due to the fact that all the patients had received standardised SLDs.

There are some important implications arising from this study. First, despite MDR/RR-TB being less prevalent among new TB cases in comparison to those with recurrent TB, the proportion of new TB cases among the absolute number diagnosed with MDR/RR-TB in our study was much lower than the expected \>90%. This coincides with the study period when the use of Xpert MTB/Rif testing was restricted only to high-risk populations and probably led to underdiagnoses of MDR/RR-TB among those with new TB. This has been addressed since the country adopted the use of Gene Xpert as the diagnostic test of choice among all presumptive TB patients in 2017.

Second, the high proportion of patients who did not have CDST results during their treatment is cause for concern as this is essential in monitoring bacteriological response to treatment. A recent study from Zimbabwe showed leakages in receipt of sputum samples at NRLs, culture contamination among received sputum specimens leading to a reduced proportion of samples with CDST results.\[[@pone.0230848.ref025]\] This CDST system will require improvements by including feedback of CDST results to facilities in order to inform patient management.

Third, we observed higher treatment success rates in comparison to what is reported to the WHO by the NTP of Zimbabwe.\[[@pone.0230848.ref001]\] The low treatment success rate reported by the NTP is a result of the high proportion of 'not evaluated' (32%) among unfavourable outcomes. The 'not evaluated' was less than 10% in the current study, where the patient records were systematically assessed. This highlights the deficiency in the routine reporting process and the NTP needs to ensure that district TB co-ordinators evaluate and report all treatment outcomes as recorded on patient 'treatment cards'.

Fourth, the high occurrence of SAEs in our study is also documented in other literature on the use of standardized MDR-TB regimens.\[[@pone.0230848.ref005],[@pone.0230848.ref017]\] The NTP needs to institute standard protocols for monitoring, recording, reporting and management of SAEs. Though the PMDT guidelines provide direction for the management of SAEs, the adherence to these guidelines has not been systematically evaluated. Currently, there is no standardized documentation of SAEs on the patient 'treatment cards'. Thus, the treatment cards need to be revisited to include space for structured documentation of SAEs and their management. The programme officers during their supervisory visits can review the 'treatment cards' for monitoring the management of SAEs. Also, the NTP could adopt individualized shorter MDR-TB treatment regimens, which has been shown to have fewer SAEs and treatment outcomes similar to standardized SLDs.\[[@pone.0230848.ref026]--[@pone.0230848.ref028]\]

Fifth, while there was a high uptake of ART among those HIV co-infected, there is a need to ensure all MDR/RR-TB patients diagnosed with HIV are initiated timely on ART in order to lessen the risk of having unfavourable outcomes. This attention should be particularly targeted at those newly diagnosed with MDR/RR-TB who are less likely to know their HIV status upon presentation with presumptive TB.

Last, a significant number of patients delayed initiation of MDR-TB treatment by more than 30 days after RR-TB diagnosis. While this was not associated with having an unfavourable outcome, this has got direct consequences at an individual level towards disease progression and at a population-level towards MDR-TB transmission in the community.

In conclusion, our findings show suboptimal MDR/RR-TB treatment success rates in this largely HIV co-infected patient population. Ensuring ART uptake among those ART-naïve patients could help in improving treatment success rates. Adoption of the new shorter treatment regimen should be considered, in view of the high occurrence of SAEs in this study. Future studies should focus on profiling management of MDR/RR-TB patients accessing care at the primary healthcare facilities in this setting.

This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Programme for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The training model is based on a course developed jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and Medécins sans Frontières (MSF). The specific SORT IT program which resulted in this publication was implemented by the Centre for Operational Research, The Union, Paris, France. Mentorship and the coordination/facilitation of this particular SORT IT workshop was provided through the Centre for Operational Research, The Union, Paris, France; the Department of Tuberculosis and HIV, The Union, Paris, France; the University of Washington, School of Public Health, Department of Global Health, Seattle, Washington, USA; National Institute for Medical Research, Muhimbili Centre, Dar es Salaam, Tanzania; and AIDS & TB Department, Ministry of Health & Child Care, Harare, Zimbabwe

The contribution by the District TB coordinators who collected the data and completed the proforma is well appreciated.

10.1371/journal.pone.0230848.r001
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Additional Editor Comments:

This paper describes the treatment outcomes of drug-resistant TB in Zimbabwe.

In addition to the Reviewer comments, I have the following comments that the authors should consider.

1\. The authors should consider revising their concluding sentence which reads \"There is a need for increased uptake of ART\". HIV status and ART status was reported at initiation of treatment. Some of the patients who are HIV positive may be newly diagnosed and may not have initiated ART yet - it would be useful to look and see if those who were HIV positive but not on ART at treatment initiation, initiated ART between 2 weeks to 2 months depending on the CD4 count (as per guidelines). You may find some of the HIV positive patients initiated ART after they initiated DR-TB, and therefore it is difficult to make inferences about treatment outcomes.

2\. Line 120 - I find the use of \"short-course\" confusing here, since the WHO has guidelines for short- and long-course DR-TB treatment. I would consider rephrasing. The reference \[2\] \"DOTS-Plus and Green Light Committee\" refers to 6-8 months with first-line anti-TB treatment.

3\. Line 134 - requires a reference for \"WHO has recommended shorter regimens\".

4\. Line 150 - Please clarify what the short course regimen is, in your setting (e.g. shorter, injectable-based, 9-12 month regimen)

4\. Line 132 - The authors refer to the shorter regimen and Line 152 - authors state that the short regimen has been rolled out in the NTP. Since the paper focuses on the standard long-course RR/MDR-TB regimen (18-24 month), between 2010 - 2015, the authors need to mention why the paper is relevant (since short course has been adopted by the NTP).

5\. Line 189 - write out \"MTB/Rif\" the first time it appears in the text; Line 192 - write out \"PTB\" the first time it appears in the text e.g. pulmonary TB (PTB); Line 224 - write out \"PMDT\" the first time it appears in the text; Line 230-233 - write out plus (+) and Lopinavir/Ritonavir and the correct abbreviation LPV/r

6\. The authors have introduced selection bias, which is a limitation of the study. The study includes MDR/RR-TB patients who initiated treatment between 2010 and 2015 and continued treatment at either district hospitals or urban polyclinics (Line 237). Those who were referred to primary health facilities were excluded (Line 239). This may contribute to why treatment outcomes are different to what is reported to the WHO by the NTP of Zimbabwe. Those who are referred to primary health facilities are considered more stable, tolerating the regimen, and live close to the PHC. These factors, including distance, have been shown to be associated with treatment outcomes, adherence to treatment and utilization of treatment services. The study population therefore presents patients who were unstable/not tolerating the regimen and/or those who lived \>10km from the health facility. The fact that the study does not include any treatment outcomes for patients referred to primary health facilities is a limitation.

7\. Line 219 - please clarify what constitutes \"stable\". What criteria is used to determine if a patient is stable?

8\. Line 252 - Please clarify how \"missed doses\" is reported. Is this patient self-report or obtained from clinical data (e.g. dispensed)?

9\. Line 269 - regarding treatment outcomes; (1) authors should refer to the WHO reporting framework and include the definitions of the outcomes, (2) authors needs to include when the outcome was defined (i.e. how long were patients followed-up for, what is the person-time?), (3) the definition of primary outcome seems unusual - can authors include a reference for this?, (4) since death and LTFU are assigned when the outcome occurs, it is more appropriate to combine death + LTFU in your outcome definition and use Cox Proportional Hazard regression

10\. Line 280 - 282 - IRB protocol numbers need to be included. Line 283 - \"health and child care\" should be corrected as in Line 282 \"Ministry of Health and Child Care\"

11\. Line 233 - Guidelines for the use of cotrimoxazole (CPT) should be included in the Methods. Please explain what this variable represents. Is this on CPT at treatment initiation or a history of CPT?

12\. Line 569 - some key variables are missing in Table 2. Examples include resistance pattern (e.g. MDR-TB, RR-TB (mono; isoniazid sensitive) or RR-TB with additional resistance unknown), time on ART, CD4 count, smear microscopy results, weight/BMI (Line 268), EPTB vs. PTB.

13\. Line 236 and Table 1 - please clarify if the study includes children? From Table 1 n=24 were \<24 years. It is not clear if this is 18-24 or 0-24? If the latter, then this should be further categorized as children (\<10) or adolescents (10-24) or further as young adolescent (10-14), older adolescent (15-19) and young adult (20-24).

14\. Table 2 Encountered SAEs - Is this during treatment or at treatment initiation. If the former, then this should be separated out from the characteristics at treatment initiation (Clarify that Table 2 includes clinical characteristics AT treatment initiation). Would be useful to include/mention the most common SAEs reported in the Table (i.e. Table 3?)

15\. Table 3 Outcomes should add up to 100% - Failed should be 0.9% and not \<1 and LTFU 8.2% (39/473). Therefore, 26.4 + 8.2 + 0.9 + 3.4 = 100%

16\. Table 4 - consider defining a resistance pattern variable - which should encompass the diagnostic test and the DST results.

17\. Table 4 - The current model ignores the time-varying nature of adherence.

18\. Figure 1 - It would be useful to present outcomes as typically reported by the WHO (e.g. see <https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf> - Page 80)

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I appreciate the work of the Authors to try to define factors associated with unfavourable outcomes in RR and MDR TB in a Country with a very high percentage of HIV co-infected patients.

I suggest the Authors to stress the need for individualized treatment regimens in order to decrease side effects (BMC Infect Dis. 2019 Jun 28;19(1):564. doi: 10.1186/s12879-019-4211-0.) and to cite the need for better treatment compliance (BMC Infect Dis. 2017 Jan 21;17(1):91. doi: 10.1186/s12879-017-2200-8. and Multidiscip Respir Med. 2018 Nov 9;13:41. doi: 10.1186/s40248-018-0154-3. eCollection 2018)

Reviewer \#2: TITLE -- Consider adding 'Urban Setting' to the title since the population belongs to urban areas and probably a bias to favorable outcome.

Abstract -- appropriate -- consider elaborating the methods.

Introduction -- Describes the problem in a complete and relevant manner. Aim of the study is well reported.

Method --

Please consider mentioning the type of phenotypic cultures utilized.

Operational definition of treatment outcomes, although standardized as per WHO -- please reiterate here, this can prevent a bit of confusion

Results --

Now as mentioned by the authors in terms of limitation -- the absence of data on management of SAE, CDST results, CD4 count and comorbidity data. I can suggest certain key data variables which are missing, if available, consider providing them.

BMI, radiological evidence of cavities as they may have direct effect on outcome as well as occupational history and smoking status of the cohort, both of which are strong risk factors for developing TB and unfavorable outcome.

It is unfortunate that DST results of fluoroquinolones and second line injectables are not available, both of which are known to be risk factors for adverse outcome, if for the \~53 cases this data can be made available and analysed as a risk factor, it will greatly strengthen your study. It is a strong point for advocating the need of DST.

Data for Time to unfavourable outcome -- is a strong variable that can help us in understanding the severity of the cohort population and help in future intervention. Did any SAE led to unfavourable outcome? The individuals who died or lost to follow up -- were recorded to be failing the regimen?

Details of ART initiation is not provided neither the status of ART success or failing is analysed.

Discussion:

The authors have done proper analysis of their results, aptly described the limitation and strengths of the study as well as compared the results with similar studies.

Please elaborate on the reason for 180 people with no recorded time for culture conversion -- they failed to culture convert or some of them died before or some could not give the sample. How many patient had their sputum culture status reverted back to positive?

Interestingly, \~14% of the study cohort was initiated on ATT beyond 30 days of RRTB diagnosis, was not found to affect the outcome. You may consider highlighting that delay in initiation for SLD.

Reviewer \#3: Please see my comments which have been attached as Microsoft Word Document. I have included all my comments in this document.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Dear Editor in Chief

Please find below a reply letter to our submission, titled:

PONE-D-19-16150: Treatment outcomes of Multi drug resistant and Rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

We thank the reviewers and the Editor for their valuable comments to our initial submission. We have attempted to address all the queries made. We provide below a point-by-point response to the queries raised and we have also provided both the clean version of the manuscript and a document with track changes.

Editor comments

Comment \#1

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response

Noted thank you. This has been addressed as per requirement

Comment \#2

In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

Response

Thank you for raising this very important ethical issue. Data was fully anonymised as only unique identifiers in the form of TB registration numbers were abstracted onto the data collection proforma in place of patient names. The Ethics committee waived the requirement for individual informed consent since this was a retrospective study and the Ministry of Health and Child Care had given permission to access patients clinical records at participating centres.

Comment \#3

Please note that all PLOS journals ask authors to adhere to our policies for sharing of data and materials: <https://journals.plos.org/plosone/s/data-availability>. According to PLOS ONE's Data Availability policy, we require that the minimal dataset underlying results reported in the submission must be made immediately and freely available at the time of publication. As such, please remove any instances of \'unpublished data\' or \'data not shown\' in your manuscript and replace these with either the relevant data (in the form of additional figures, tables or descriptive text, as appropriate), a citation to where the data can be found, or remove altogether any statements supported by data not presented in the manuscript

Response

Thank you for raising this. The data not shown on distribution and type of severe adverse events has now been added as Table 3.

Comment \#4

Our internal editors have looked over your manuscript and determined that it is within the scope of our Antimicrobial Resistance call for papers. This collection of papers is headed by a team of Guest Editors for PLOS ONE: Kathryn Holt (Monash University and London School of Hygiene and Tropical Medicine), Alison H. Holmes (Imperial College London), Alessandro Cassini (WHO Infection Prevention and Control Global Unit), Jaap A. Wagenaar (Utrecht University). The Collection will encompass a diverse range of research articles; additional information can be found on our announcement page: <https://collections.plos.org/s/antimicrobial-resistance>. If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

Response

Thank you for considering our manuscript for the PLOS ONE collection on Antimicrobial Resistance. We would like to express our interest to have our manuscript considered as such and we give you explicit permission to process accordingly. We have indicated our interest in the attached cover letter

Comment \#6

We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Response

Thank you for the comment. Unfortunately we are not permitted to share our dataset due to our local ethics clearance committee and the Ministry of Health and Child Care who are the custodians of all data related to the National TB Programme. We have provided details of institutional heads for both organizations in the cover letter as requested.

Comment \#7

We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Response

The data that were not shown have now been added as "Table 3".

Additional Editor Comments:

Comment \#1

In addition to the Reviewer comments, I have the following comments that the authors should consider.

1\. The authors should consider revising their concluding sentence which reads \"There is a need for increased uptake of ART\". HIV status and ART status was reported at initiation of treatment. Some of the patients who are HIV positive may be newly diagnosed and may not have initiated ART yet - it would be useful to look and see if those who were HIV positive but not on ART at treatment initiation, initiated ART between 2 weeks to 2 months depending on the CD4 count (as per guidelines). You may find some of the HIV positive patients initiated ART after they initiated DR-TB, and therefore it is difficult to make inferences about treatment outcomes.

Response

Thank you. In our study, dates on when ART was initiated in relation to commencement of TB treatment were not collected. However, the ART status of those who newly tested HIV-positive are supposed to be updated in the DR-TB register throughout their course of MDR-TB treatment period together with date of ART initiation although the information of ART start dates were missing in our case. As a result this limits our capabilities to determine impact of ART timing on DR-TB treatment outcomes, however we feel there is merit to conclude that ART does improve DR-TB treatment outcomes. Instead we have added to the abstract the following sentence: "Assessing timing of ART initiation in relation to TB treatment outcomes will also require future exploration." We hope this response is satisfactory.

Comment \#2

2\. Line 120 - I find the use of \"short-course\" confusing here, since the WHO has guidelines for short- and long-course DR-TB treatment. I would consider rephrasing. The reference \[2\] \"DOTS-Plus and Green Light Committee\" refers to 6-8 months with first-line anti-TB treatment.

Response

Noted, the term "Short course" has been removed and the sentence now reads as follows: "In 2000, WHO recommended the 20-24 month standardized second-line drug (SLDs) regimens for treatment of MDR/RR-TB patients in resource-limited settings". We have also removed the reference \[2\] on the DOTS-Plus and the Green Light Committee.

Comment \#3

3\. Line 134 - requires a reference for \"WHO has recommended shorter regimens\".

Response

Thank you. We have now referenced the 2019 WHO consolidated guidelines on drug-resistant tuberculosis treatment.

Comment \#4

4\. Line 150 - Please clarify what the short course regimen is, in your setting (e.g. shorter, injectable-based, 9-12 month regimen)

Response

Noted, thank you. Now clarified and it reads: "In 2016, the short treatment regimen which is over 9-11 months and injectable based was adopted"

Comment \#4 (Duplication of numbering)

Line 132 - The authors refer to the shorter regimen and Line 152 - authors state that the short regimen has been rolled out in the NTP. Since the paper focuses on the standard long-course RR/MDR-TB regimen (18-24 month), between 2010 - 2015, the authors need to mention why the paper is relevant (since short course has been adopted by the NTP).

Response

The short treatment course was piloted since June 2018 and is made available only in a few districts. Even in districts where short regimen is available, very few patients are started on it due to issues in assessing eligibility. Up to now most districts are still implementing the 18-24 month regimen. The short regimen might have been initiated in less than 5% patients. The study is relevant as it informs on the treatment outcomes with longer regimens and also provides a baseline estimate for tracking the successful outcomes rates with scale up of short regimen in future.

Comment \#5

5\. Line 189 - write out \"MTB/Rif\" the first time it appears in the text; Line 192 - write out \"PTB\" the first time it appears in the text e.g. pulmonary TB (PTB); Line 224 - write out \"PMDT\" the first time it appears in the text; Line 230-233 - write out plus (+) and Lopinavir/Ritonavir and the correct abbreviation LPV/r

Response

Line 189-\"MTB/Rif\" now appears in full the first time it appears in the text

Line 192-"PTB" now appears as "Pulmonary TB" the first time it appears in the text

Line 224-"PMDT\" written in full the first time it appeared in line 149.

Line 230-233- Lopinavir/Ritonavir) (ABC + 3TC + EFV now reflected and LPV/r now reflected

Comment \#6

6\. The authors have introduced selection bias, which is a limitation of the study. The study includes MDR/RR-TB patients who initiated treatment between 2010 and 2015 and continued treatment at either district hospitals or urban polyclinics (Line 237). Those who were referred to primary health facilities were excluded (Line 239). This may contribute to why treatment outcomes are different to what is reported to the WHO by the NTP of Zimbabwe. Those who are referred to primary health facilities are considered more stable, tolerating the regimen, and live close to the PHC. These factors, including distance, have been shown to be associated with treatment outcomes, adherence to treatment and utilization of treatment services. The study population therefore presents patients who were unstable/not tolerating the regimen and/or those who lived \>10km from the health facility. The fact that the study does not include any treatment outcomes for patients referred to primary health facilities is a limitation.

Response

Thank you very much for concurring with the authors that the study had some limitations as referred above. The above Editor concern has been articulated at length as a study limitation and authors acknowledged this quite extensively

Comment \#7

7\. Line 219 - please clarify what constitutes \"stable\". What criteria is used to determine if a patient is stable?

Response

"Stable" is a term used to describe those patients who were able to ingest medication, did not show signs of adverse drug reaction and had all the laboratory investigations within normal limit. This description now appears in line 219

Comment \#8

8\. Line 252 - Please clarify how \"missed doses\" is reported. Is this patient self-report or obtained from clinical data (e.g. dispensed)?

Response

"Missed doses" are determined from patient clinical records specifically from the patient treatment card. As the directly observed treatment is provided, the 'right tick' is made against the particular date in the treatment card by the clinician when drugs are consumed. In case if the patient fails to report for DOT at the health facility, a follow up is done and in the event the patient is not located and misses his drugs for that day, it is marked as missed with 'wrong' tick against that date. We considered all the 'wrong' tick till the date of treatment outcome as 'Missed doses', Later we calculated the percentage of missed doses per total number of days the patient was receiving the treatment.

Comment \#9

9(1) Line 269 - regarding treatment outcomes; (1) authors should refer to the WHO reporting framework and include the definitions of the outcomes.

Response

Noted. "Table of Treatment Outcomes definition" referred as Fig 2

9(2) authors needs to include when the outcome was defined (i.e. how long were patients followed-up for, what is the person-time?), (3) the definition of primary outcome seems unusual - can authors include a reference for this?, (4) since death and LTFU are assigned when the outcome occurs, it is more appropriate to combine death + LTFU in your outcome definition and use Cox Proportional Hazard regression

Response

Patient TB treatment outcomes were defined at 24 months from date of each patients MDR-TB treatment start date until date of their respective outcomes for deaths, LTFUs, treatment failure and "outcome not evaluated". Those classified as LTFU were defined as a patient whose MDR-TB treatment was interrupted for two or more consecutive months for any reason as per WHO guidelines. Those cured or who completed their treatment were categorized as successful treatment outcomes, whereas the others were categorized as unsuccessful treatment outcomes in line with recent meta-analysis studies by Kibret et al and Johston JC et al. We have added this to the data analysis section of our paper

The 473 patients in our study contributed 672.5 person-years. We have added this to the first paragraph of the results section. Thank you for suggesting that we use Cox Proportional Hazards regression. We considered this at length as the most appropriate analysis method, however we finally abandoned it because there were a number of patients who had missing dates on treatment outcomes hence this would lower our sample size.

Comment \#10

10\. Line 280 - 282 - IRB protocol numbers need to be included. Line 283 - \"health and child care\" should be corrected as in Line 282 \"Ministry of Health and Child Care\"

Response

Line 280 - 282 - IRB protocol numbers now included.

Line 283 - \"health and child care\"- Both sentences line 282 and 283 read as "Ministry of Health and Child Care" from original texts

Comment \#11

Line 233 - Guidelines for the use of cotrimoxazole (CPT) should be included in the Methods.

Response

A reference for the guidelines of use of Cotrimoxazole Preventive Therapy is now indicated and the reference section has been updated

Comment \#12

12\. Line 569 - some key variables are missing in Table 2. Examples include resistance pattern (e.g. MDR-TB, RR-TB (mono; isoniazid sensitive) or RR-TB with additional resistance unknown), time on ART, CD4 count, smear microscopy results, weight/BMI (Line 268), EPTB vs. PTB.

Response

Thank you for observing that some key variables are missing in Table 2. All the above are missing data as explained in the section on study limitations

Comment \#13

13\. Line 236 and Table 1 - please clarify if the study includes children? From Table 1 n=24 were \<24 years. It is not clear if this is 18-24 or 0-24? If the latter, then this should be further categorized as children (\<10) or adolescents (10-24) or further as young adolescent (10-14), older adolescent (15-19) and young adult (20-24).

Response

The study does include children. We had collapsed the age groups \<24 years because of small numbers, however we have reverted back to the disaggregation of \<5, 5-14 and 15-24 years in Table 1 but however maintained the combined age group of \<24 years in the multivariate regression analysis table so as to allow for adequate numbers for calculating relative risks and their 95% confidence intervals. We also used the age categories \<24, 25-34, 35-44, 45-54 and 55+ years as these are the standard age groups for reporting TB data to WHO and are also used in several studies to allow for comparisons.

Comment \#14

14\. Table 2 Encountered SAEs - Is this during treatment or at treatment initiation. If the former, then this should be separated out from the characteristics at treatment initiation (Clarify that Table 2 includes clinical characteristics AT treatment initiation). Would be useful to include/mention the most common SAEs reported in the Table (i.e. Table 3?)

Response

Thank you for the point. The encountered SAEs were during treatment and we have rephrased the variable as "Encountered SAE during treatment". Seeing that some patients may have also initiated ART during MDR-TB treatment and that we have the variable on missed treatment dosses in this table, we have instead rephrased the table title as "Clinical characteristics of MDR/RR-TB patients at baseline and/or during treatment among MDR/RR-TB patients initiated on treatment in Zimbabwe, 2010-2015". We hope that this is satisfactory.

Comment \#15

15\. Table 3 Outcomes should add up to 100% - Failed should be 0.9% and not \<1 and LTFU 8.2% (39/473). Therefore, 26.4 + 8.2 + 0.9 + 3.4 = 100%

Response

Many thanks for pointing this out. We have replaced the percentage for those with treatment failure with 0.8% however we note that the percentages for the different end-of-TB treatment outcomes add up to 99.9% due to rounding-off errors. We have specified this as a footnote to the table.

Comment \#16

16\. Table 4 - consider defining a resistance pattern variable - which should encompass the diagnostic test and the DST results.

Response

Thank you for the comment. This information was not available due to missing data on CDST results which the authors highlighted as a study limitation in the discussion section.

Comment \#17

17\. Table 4 -- The current model ignores the time-varying nature of adherence.

Response

This is indeed a valid comment and we ought to have included missed doses as a time dependent variable in our univariate and multivariate-adjusted regression models. However, we did not have data on the specific time points when MDR-TB treatment doses were missed as these were aggregated for each patient by the time they achieved their treatment outcome

Comment \#18

18\. Figure 1 - It would be useful to present outcomes as typically reported by the WHO (e.g. see <https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf> - Page 80)

Response

Thank you for the comment. The term "Unfavourable Outcome" has been further clarified in the text as per WHO reporting system (Death, Treatment failure, LTFU and Not Evaluated)

Reviewer \#1:

I appreciate the work of the Authors to try to define factors associated with unfavourable outcomes in RR and MDR TB in a Country with a very high percentage of HIV co-infected patients.

I suggest the Authors to stress the need for individualized treatment regimens in order to decrease side effects (BMC Infect Dis. 2019 Jun 28;19(1):564. doi: 10.1186/s12879-019-4211-0.) and to cite the need for better treatment compliance (BMC Infect Dis. 2017 Jan 21;17(1):91. doi: 10.1186/s12879-017-2200-8. and Multidiscip Respir Med. 2018 Nov 9;13:41. doi: 10.1186/s40248-018-0154-3. eCollection 2018)

Response

The authors appreciate this valid comment. On study implications, line 409, the authors stresses the need for NTP to adopt shorter treatment regimen for MDR-TB treatment which has been shown to have fewer SAEs. A reference has been added and cited in the reference section as advised

Line 417, the authors stresses the need to ensure that patients do not have missed doses during MDR-TB treatment in order to lessen their risk of having unfavourable outcomes. . A reference has been added and cited in the reference section as advised.

Reviewer \#2:

TITLE -- Consider adding 'Urban Setting' to the title since the population belongs to urban areas and probably a bias to favorable outcome.

Response

Thank you for raising this important point, however the study was not primarily set for the urban population as some district hospitals serve mostly rural populations thus the study population was both urban and rural

Abstract -- appropriate -- consider elaborating the methods.

Response

Thank you for this comment. The methods section of the abstract has been elaborated as advised. The following statement has been added "A generalized linear model with a log-link and binomial distribution or a poisson distribution with robust error variances were used assess factors associated with "unfavorable outcome". The unadjusted and adjusted relative risks were calculated as measure of association. A �value\< 0.05 was considered statistically significant".

Introduction -- Describes the problem in a complete and relevant manner. Aim of the study is well reported.

Response

Thank you, well appreciated

Comment

Method -- Please consider mentioning the type of phenotypic cultures utilized.

Response

Thank you. The type of phenotypic cultures utilized is now indicated as BBLTM MGITTM Mycobacterial Growth Indicator Tubes (Becton Dickinson, Sparks, MD

Comment

Operational definition of treatment outcomes, although standardized as per WHO -- please reiterate here, this can prevent a bit of confusion

Response

Noted, Fig 2 has been added to clarify

Comment

Results -- Now as mentioned by the authors in terms of limitation -- the absence of data on management of SAE, CDST results, CD4 count and comorbidity data. I can suggest certain key data variables which are missing, if available, consider providing them.

BMI, radiological evidence of cavities as they may have direct effect on outcome as well as occupational history and smoking status of the cohort, both of which are strong risk factors for developing TB and unfavorable outcome

Response

We thank you for raising this very valid comment. As already mentioned as study limitations, the data suggested was missing and cannot be included

Comment

It is unfortunate that DST results of fluoroquinolones and second line injectables are not available, both of which are known to be risk factors for adverse outcome, if for the \~53 cases this data can be made available and analysed as a risk factor, it will greatly strengthen your study. It is a strong point for advocating the need of DST.

Response

Thank you for the comment. Of all the second-line injectables and flouroquinolones in use (i.e. kanamycin, Levofloxacin, Moxifloxacin and Cycloserine and Capriomycin alone as an alternative to those intolerant to kanamycin), only 3 patients were resistant to any one of the above hence we could not include this variable in the univariate and multivariate regression analysis because of the small numbers.

Comment

Data for Time to unfavourable outcome -- is a strong variable that can help us in understanding the severity of the cohort population and help in future intervention. Did any SAE led to unfavourable outcome? The individuals who died or lost to follow up -- were recorded to be failing the regimen?

Response

Thank you for raising this very important observation. In our univariate and multivariate regression encountering an SAE was not significant predictor of an unfavourable outcome as shown in Table 5. Also, due to deficiencies in our data and this being a retrospective study, we failed to assess the cause-effect relationship of SAEs and unfavourable outcome

Comment

Details of ART initiation is not provided neither the status of ART success or failing is analysed.

Response

Thank you. Unfortunately data on virological, immunological or clinical failure of patients initiated on ART were not available in the DR-TB registers hence required matching patient names to the ART registers given that there was no unique identifier linking the ART and MDR-TB programmes. However we do acknowledge the importance of this data and is something that was worth exploring and should be explored in future studies.

Comment

Discussion:

The authors have done proper analysis of their results, aptly described the limitation and strengths of the study as well as compared the results with similar studies.

Response

Thank you, comment well appreciated

Comment

Please elaborate on the reason for 180 people with no recorded time for culture conversion -- they failed to culture convert or some of them died before or some could not give the sample

Response

Thank you for asking us to elaborate. These patients either did not have their samples examined because of contamination, spillages or did not have results (CDST) sent back to the health facility and the reasons are well explained under the section on study implications where the authors mentioned that the high proportion of patients who did not have CDST results during their treatment is cause for concern as this is essential in monitoring bacteriological response to treatment. A recent study from Zimbabwe showed leakages in receipt of sputum samples at NRLs, culture contamination among received sputum specimens leading to a reduced proportion of samples with CDST results and this was mentioned in the relevant section. The authors concluded by stressing that this CDST system will require improvements including feedback of CDST results to facilities in order to inform patient management.

Comment

How many patient had their sputum culture status reverted back to positive

Response

Thank you for this question. None had their sputum culture status reverted back to positive

Comment

Interestingly, \~14% of the study cohort was initiated on ATT beyond 30 days of RRTB diagnosis, was not found to affect the outcome. You may consider highlighting that delay in initiation for SLD.

Response

Thank you for pointing this out. We have mentioned the following in the discussion section: "Last, a significant number of patients delayed initiation of MDR-TB treatment by more than 30 days after RR-TB diagnosis. Whilst this was not associated with having an unfavourable outcome, this has got dire consequences at an individual level towards disease progression and at a population-level towards MDR-TB transmission in the community."

Reviewer \#3:

Comment \#1

Background is unclear and does not adequately contextualize the aims of the manuscript.

Response

Thank you for the comment. This study aimed at assessing the profile, treatment outcomes and factors associated with unfavourable treatment outcomes among patients initiated on MDR/RR-TB treatment. In view of this we started by highlighting the global burden of MDR/RR-TB and also mentioned the WHO MDR/RR-TB treatment targets as a benchmark to assess our poor performance in this regard. We further summarised some of the literature of risk factors associated with poor MDR-TB treatment outcomes before we highlighted the paucity of data on treatment outcome determinants in our setting. This is of interest to the Zimbabwe NTP in order to have tailored interventions aimed at improving our overall MDR-TB treatment success rate. We do appreciate your comment and would like your further guidance on specific sections that require rewriting in order to make the introduction more appealing.

Comment \#2

Methods lack clarity on how outcomes were defined, time-points at which outcomes were assessed by, measurement of covariates like adverse events is not suitable, inferential analytic techniques are also questionable.

Response

Thank you for this comment. We have addressed your comment on outcome definitions and time-points for assessment of these outcomes are addressed in the data entry and analysis section in line with other reviewers comments. As for inferential analytical techniques, we would have preferred to use Cox Hazards regression analysis to generate hazard ratios, however due to a large proportion of missing data on time of outcomes, we resorted to generating relative risk instead. Also, as our outcome of interest in this manuscript is 'unfavourable outcome', which includes 'death', LTFU, failure and 'not evaluated' we considered binomial regression. If at all we were modelling for death or LTFU than the Cox Hazard regression would have been the only option.

Comment \#3

Results are sparse and could be described in greater detail.

Response

Thank you. In our analysis, we generated tables that responded to each of our set specific objectives and were hesitant to delve into greater detail for fear of digressing from our set objectives. However, we would appreciate if you can specify particular detail which would be of interest to the readers of our paper and is also aligned with our study objectives.

Comment \#4

It is not very clear how background, aims, methods, results tie into the discussion and conclusions.

Response

Thank you for the comment. We are however surprised that this is the case as your comment is contradictory to the other 2 reviewers. In writing the paper we carefully attempted to logically align our discussion to the results presented which in turn were informed by the background, aims and methods of the study. We hope this is understandable with you

Comments:

1\. Keywords

a\. Repeated (full-text and abbreviations used for the same word)

Response

We have gone through the whole manuscript and ensured that full-text and abbreviations are reported together only once, following which only abbreviations are mentioned were necessary.

a\) Background

Comment

Tuberculosis to be written out in full before abbreviated

Response

Thank you. Tuberculosis now written out in full the first time it is used before being abbreviated

Comment

Incorrect order of abbreviations for RR/MDR-TB. Authors write this out in full starting with MDR-TB.

Response

Thank you for this. We appreciate that MDR/RR-TB can be written as RR/MDR-TB however after careful consideration, the study investigator team opted to align with MDR/RR-TB which is used in the WHO global TB reports and guidelines. We hope this is understandable.

Comment

Please rephrase last sentence. This is unclear

Response

Thank you for the comment. The last sentence on the background now rephrased and reads "The profile, management, and factors associated with unfavourable treatment outcomes of MDR/RR TB have not been systematically evaluated in Zimbabwe".

Comment

b\) Design

1\) Please provide more detail regarding the methods you employ to assess treatment outcomes and risk factors for such outcomes. Study sites, participants, data collected, analytic methods used, definition of outcomes assessed, time point outcomes were assessed by etc.

Response

Study sites were all district hospitals and urban polyclinics in Zimbabwe. The study participants were all MDR/RR-TB patients initiated on treatment between 2010-2015 under the Zimbabwe NTP and continued their treatment in the above mentioned health facilities. This information is stated in the section on "Study Population". We have further on added the total number of district hospitals and urban polyclinics which totalled eighty-two under study design. As per your earlier request we have specified the time point outcomes assessed in the "Data entry and analysis" section.

2\) How were participants selected for the final analysis?

Response

We thank you for asking us to explain. Of the total 935 MDR/RR-TB patients initiated on treated during study reference period , the 473 (51%) of patients who met the study inclusion criteria of those started on MDR/RR-TB treatment and continued their 20-24 month treatment at district and urban polyclinics were all included in the study

Comment

c\) Results

i\. How was missing MDR-TB treatment doses defined? Please add to methods.

Response

Thank you. Percentage of missed doses is defined as percentage of the number of days with missed doses divided by the total number of days a patient was on treatment up until date of outcome. This has been added to methods section

Comments

ii\. Did outcomes differ between RR-TB and MDR-TB?

Response

Thank you for this valid comment. As shown in Table 5, based on the individual analysis of isoniazid, streptomycin and ethambutol resistant patterns at baseline, there were no differences in outcomes between RR-TB and MDR-TB patients. Furthermore, it is difficult to conclusively distinguish between RR-TB and MDR-TB patients as the majority of patients did not have DST results recorded or at least for all second-line TB drugs..

Comment

iii\. How were covariates selected to be included in the main effects model? Please add to methods.

Response

Thank you for the comment. All covariates with a p\<0.25 and those that are biologically plausible predictors of unfavourable outcomes were added to the multivariate regression model. This is mentioned in the "Data entry and analysis" section.

Comment

iv\. Why was 'not evaluated' outcome considered unfavourable?

Response

Those "not evaluated" were included in those with unfavourable outcomes as stated in the "Data entry and analysis" section in line with recent meta-analysis studies by Kibret et al and Johston JC et al. The WHO in its annual TB report, considers 'not evaluated' as 'unfavourable' or 'unsuccessful' outcome

Comment

d)Conclusion

v\. Stating that outcomes were poor coupled with high occurrence of adverse events make it seems like this was a significant risk factor -- but it wasn't?

Response

Thank you for the comment. Whilst we acknowledge that adverse events were not a significant risk factor, in paragraph 6 of the discussion section we only highlight that the high proportion of SAEs in this patient cohort (i.e. one in four patients) is a cause for concern and do not insinuate that this is a risk factor for unfavourable outcomes. We further advocate for more standardized recording and reporting of SAEs for better tracking by the NTP and also advocate for wider adoption of the shorter MDR-TB treatment regimen

Comment

vi\. Conclusions and recommendations are based on adverse events; however this is not mentioned as a significant predictor in the results. Therefore, how are these conclusions relevant to your findings?

Response

Thank you. Please refer to the earlier response above.

2\. Introduction -Comment

i\. Capitalize 'tuberculosis' line 112

Response

"T" Now in capital letters

Comment

ii\. Don't start a sentence with an abbreviation -- line 114 and other places within the text

Response

Line 114 and 118 corrected

Comment

Insert "The" before World Health Organisation

Response

The World Health Organization' -- line 116

"The" Inserted

Comment

iii\. Line 120 -- is this reference from 2000?

Response

Thank you. Yes, we can confirm that the reference is from 2000

Comment

iv\. Line 128-129 -- please clarify what the second part of this sentence means

Response

The authors of the systematic review paper stated that studies included in the review were largely from countries with low HIV coinfection. They then recommended for systematic assessment of treatment outcomes in high HIV coinfection countries of sub-Saharan Africa

Comment

v\. Could you comment on the incidence of ADRs on second-line TB treatment? Line 130-134

Response

Thank you for raising this comment. We could not generate incidence rate of ADRs as we did not have data on time of their occurrence.

Comment

vi\. Could you comment on eligibility for newer shorter regimens? Line 130-134

Response

Thank you for asking us to comment. Eligibility for newer shorter regimens is when there is no risk or confirmed resistance to any second line medicines or any medicine used in the shorter treatment regimen

Comment

vii\. However, unsure of commenting on newer short course regimens -- what does this have to do with assessing treatment outcomes in your traditional-long course cohort? Shorter regimens may be more pertinent in your discussion.

Response

Our apologies as we do not clearly understand your comment. If we understand well, you suggest that we mention the importance of the newer short course regimen as an alternative to the traditional long course regimen. We have touched on this in paragraph 10 of the discussion section were we suggest that the NTP should adopt wider scale up of the shorter treatment regimen which has fewer SAEs although treatment outcomes are comparable to the long MDR-TB treatment regimen.

3\. Methods

Comment

viii\. Could a figure describing the general setting be included to better understand the public healthcare setting? And thereafter selection process

Response

Thank you for suggesting this. We have attempted to present this information graphically but have concluded that the text description mentioned in the General setting and the description of diagnosis and treatment of MDR/RR-TB gives an overall description of Zimbabwe's public health setting in the context of the National TB Programme. We are happy to clarify any specific sections that are unclear to you.

Comment

ix\. Line 212-213 -- WHO recommended DOTS-plus during the study period? Or as above in 2000?

Response

In 2000, Tense changed to reflect "Was" instead of "be"

Comment

x\. Line 237 -238 please rephrase

Response

Rephrased as per reviewer 3 comments, sentence now short and more precise

Comment

xi\. Would patients referred for DOTS-plus who were then excluded from the analysis be systematically different to those who were included?

Response

Yes we do acknowledge this possibility given that the treatment success rate for our study population was better than that reported by the NTP for all patients due to their high proportion of unevaluated patients. Furthermore in rural settings health facilities are less accessible due to long distances from households and there is less specialized care in rural facilities. We have stated this as a limitation in the discussion section.

Comment

xii\. Line 243 -- consistency with capitalization

Response

We have noted this and addressed it accordingly.

Comment

xiii\. Data quality between sites could differ? Were there any systematic differences between quality (missing data) etc. between sites?

Response

Thank you for this comment, however there were no systematic differences between sites in terms of data quality. Missing data was across all sites because the tools used by all sites were the same and no data was collected on those variables. Also all the sites sent their samples to the same reference laboratory which did not give results back on CDST. Furthermore 10%of the data was subjected to quality assurance and originally missing data was completed before final data entry.

Comment

xiv\. Since the primary outcome of interest is death and LTFU which can occur any time from treatment initiation -- would you consider using a Cox Hazard Model to determine hazard ratio estimates of 'unfavourable outcomes'? Considering time to outcome may be an important factor which could be affected differently by different risk factors. Furthermore, was LTFU and death separated and did risk factors differ by these outcomes? Lastly, what is the motivation for including 'not evaluated' as an 'unfavourable outcome'?

Response

As mentioned above we could not perform Cox Hazard regression analysis due to the high proportion of missingness on time to event data. We also reserved further comparisons on any differences between predictors of mortality and LTFU for another paper as we felt this was too much information for one paper. We hope reviewers understand our position.

Comment

xv\. Please include a time-point at which outcomes were assessed by. Did everyone have a minimum follow-up etc.?

Response

Yes, since this was a retrospective cohort study based on routinely collected programme data, all patients were allowed a follow-up period for their potential 20-24 month MDR-TB treatment duration.

Comment

3Results

xvi\. Line 287 -- punctuation

Response

Thank you, we consider the punctuation used to be fine and appropriate as "Ethics approval was granted by The Union Ethics Advisory Group of the International Union against Tuberculosis and Lung Diseases, Paris, France, IRB number EAG 53/18 and the Medical Research Council of Zimbabwe (MRCZ), IRB number MRCZ/A/2331"

Comment

xvii\. Measurement of adverse events seems to have been recorded throughout treatment for respective patients. If so, this cannot be included as a potential risk factor in the predictive analysis as results would be prone to systematic bias. Those who remain in care long enough to develop and record ADRs will be different from those who do not. If ADRs are to be included, this should be recorded within a pre-defined period around baseline i.e., within 14 days after starting treatment for example. Thereafter, the analysis should be rerun.

Response

Thank you for the valid comment. We have removed SAEs from the multivariate regression model.

Comment

xviii\. Table 4 -- stepwise approach to model selection given in methods -- but no p-values shown in table?

Response

Thank you for raising this comment. We did not include p-values as they would be redundant given that the reported univariate and multivariate-adjusted relative risks with 95% confidence intervals are more informative. When the 95%CI doesn't cross the null value, then the factor is significant.

Comment

xix\. How would the reader interpret significant risk factors for variables with categories that were 'not recorded'? i.e., streptomycin DST pattern, Ethambutol DST pattern? Isoniazid DST pattern, missed doses?

Response

We appreciate your comment, however the interpretation for unrecorded data will be largely not make programmatic interpretation especially for the "missed doses" variable. We however included all the patients with unrecorded data in the univariate and multivariate-adjusted regression models for the selected variables since excluding them will greatly diminish the eligible sample given the large amount of missing data as is often the case with routinely collected programme data.

Comment

3\. Discussion

i\. Line 316-324 -- please rephrase language used here.

Response

Thank you. Rephrased to make the statement clearer as" The proportion with an unfavourable treatment outcome (death, Treatment failure, LTFU and Not evaluated) increased annually from 0% in 2010 to 45% in 2015 (Figure-1).

Factors associated with an unfavourable outcome among patients on MDR-TB treatment are shown in Table 4.

Those who were HIV-positive and ART-naive (ARR=2.83; 95% CI: 1.44-5.57) and those who missed \>10% of their MDR-TB treatment dosses (ARR=2.41; 95% CI: 1.59-3.67) were more likely to have an unfavourable treatment outcome

Comment

ii\. Line 325-326: what was the breakdown of patients across sites? Did some sites have a disproportionally higher number of patients?

Response

Thank you for the comment. Fifty-two out of sixty-three district hospitals that notified an MDR/RR TB patient during 2010-2015 contributed different numbers of the patients included in the study who were not refered to rural health centres. Thirty polyclinics from the two metro-politan provinces also contributed varied numbers but less patients per site as compared to what the district hospitals notified.

Across sites, yes the numbers were different depending on various factors as per the inclusion criteria described in the study design.

Comment

iii\. Please consider the use of language in the strength and limitations sections of the discussion.

Response

The language used is deemed appropriate for a scientific paper as it arranges the strengths and limitations as first, second, third etc thus allowing the reader to follow the sequence of the issues highlighted.

Comment

iv\. Line 328 -- how were operational challenges assessed in this analysis?

Response

Since this study was based on a retrospective review of routine patient records. Therefore we did not conduct a process evaluation which would have been useful in determining operational challenges encountered in treatment and management of patients on MDR-TB treatment

Comment

v\. Line 336 and 337 seems to be in contradiction to line 325-326

Response

Thank you for the observation, we however think there is no contradiction as a district has both urban and rural population. The participants included in our study were predominantly from the urban part of the district yet those that were excluded were predominantly from the rural part of the same district. It is not necessarily correct to assume that districts have only rural population

Comment

vi\. Line 343-344 -- if these changes were assessed during treatment, I'm not sure they would be suitable in your predictive analysis for the reasons of systematic bias as mentioned above

Response

Thank you. Comorbidities were determined during eliciting patient history at MDR-TB treatment initiation. We have revisited line 343-344 and specified this.

Comment

vii\. Line 357-359 -- could you comment on time on ART

Response

Thank you. unfortunately data on ART initiation start dates were not available in the DR-TB registers hence we could not assess timing of ART in relation to MDR-TB treatment commencement. We have added this as a limitation to paragraph of the discussion section.

Comment

viii\. Line 363 -- still unsure of exactly how missed doses was defined? Please could this be clarified in the methods.

Response

Thank you, Missed doses are clearly defined under Methods (Operational Definitions) Line 255 as percentage of the number of days with missed doses divided by the total number of days a patient was on treatment up until date of outcome.

Comment

ix\. Line 387 -- at what time-point was cured/completed outcomes assessed? Was this by 24 months on treatment? As mentioned above -- the time point at which outcomes were assessed is not clear here.

Response

Thank you. Time point of cured/completed outcomes was assessed at the end of treatment duration.

Comment

x\. Line 411 -- could you provide a measure of time between missed doses in the results section.

Response

Thank you. The following statement has been added to the results section under implications of study results: " If a patient consecutively misses doses of two months or more, the patient is considered lost to follow-up and will restart treatment upon return".

Comment

xi\. Line 419-423 -- it is still not clear how findings presented here link to the conclusions presented.

Response

Our conclusions were linked to our major study findings which are as follows: 1) the MDR-TB treatment success rate was lower than the WHO treatment success target 2) treatment outcomes were better among those on ART whilst 3) missed doses of more than 10% were associated with poor outcomes. In addition, we have also made mention of the high occurrence of SAEs

We thank Reviewer 1, 2 and 3 including the Editor for a thorough review and hope we have satisfactorily addressed all the grey areas. We are more than pleased to attend to any further comment that may require a follow-up response

28 August 2019

PLOS ONE

Dear Editor in Chief

Please find below a reply letter to our submission, titled:

PONE-D-19-16150: Treatment outcomes of Multi drug resistant and Rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

We thank the reviewers and the Editor for their valuable comments to our initial submission. We have attempted to address all the queries made. We provide below a point-by-point response to the queries raised and we have also provided both the clean version of the manuscript and a document with track changes.

Editor comments

Comment \#1

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response

Noted thank you. This has been addressed as per requirement

Comment \#2

In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

Response

Thank you for raising this very important ethical issue. Data was fully anonymised as only unique identifiers in the form of TB registration numbers were abstracted onto the data collection proforma in place of patient names. The Ethics committee waived the requirement for individual informed consent since this was a retrospective study and the Ministry of Health and Child Care had given permission to access patients clinical records at participating centres.

Comment \#3

Please note that all PLOS journals ask authors to adhere to our policies for sharing of data and materials: <https://journals.plos.org/plosone/s/data-availability>. According to PLOS ONE's Data Availability policy, we require that the minimal dataset underlying results reported in the submission must be made immediately and freely available at the time of publication. As such, please remove any instances of \'unpublished data\' or \'data not shown\' in your manuscript and replace these with either the relevant data (in the form of additional figures, tables or descriptive text, as appropriate), a citation to where the data can be found, or remove altogether any statements supported by data not presented in the manuscript

Response

Thank you for raising this. The data not shown on distribution and type of severe adverse events has now been added as Table 3.

Comment \#4

Our internal editors have looked over your manuscript and determined that it is within the scope of our Antimicrobial Resistance call for papers. This collection of papers is headed by a team of Guest Editors for PLOS ONE: Kathryn Holt (Monash University and London School of Hygiene and Tropical Medicine), Alison H. Holmes (Imperial College London), Alessandro Cassini (WHO Infection Prevention and Control Global Unit), Jaap A. Wagenaar (Utrecht University). The Collection will encompass a diverse range of research articles; additional information can be found on our announcement page: <https://collections.plos.org/s/antimicrobial-resistance>. If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

Response

Thank you for considering our manuscript for the PLOS ONE collection on Antimicrobial Resistance. We would like to express our interest to have our manuscript considered as such and we give you explicit permission to process accordingly. We have indicated our interest in the attached cover letter

Comment \#6

We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Response

Thank you for the comment. Unfortunately we are not permitted to share our dataset due to our local ethics clearance committee and the Ministry of Health and Child Care who are the custodians of all data related to the National TB Programme. We have provided details of institutional heads for both organizations in the cover letter as requested.

Comment \#7

We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Response

The data that were not shown have now been added as "Table 3".

Additional Editor Comments:

Comment \#1

In addition to the Reviewer comments, I have the following comments that the authors should consider.

1\. The authors should consider revising their concluding sentence which reads \"There is a need for increased uptake of ART\". HIV status and ART status was reported at initiation of treatment. Some of the patients who are HIV positive may be newly diagnosed and may not have initiated ART yet - it would be useful to look and see if those who were HIV positive but not on ART at treatment initiation, initiated ART between 2 weeks to 2 months depending on the CD4 count (as per guidelines). You may find some of the HIV positive patients initiated ART after they initiated DR-TB, and therefore it is difficult to make inferences about treatment outcomes.

Response

Thank you. In our study, dates on when ART was initiated in relation to commencement of TB treatment were not collected. However, the ART status of those who newly tested HIV-positive are supposed to be updated in the DR-TB register throughout their course of MDR-TB treatment period together with date of ART initiation although the information of ART start dates were missing in our case. As a result this limits our capabilities to determine impact of ART timing on DR-TB treatment outcomes, however we feel there is merit to conclude that ART does improve DR-TB treatment outcomes. Instead we have added to the abstract the following sentence: "Assessing timing of ART initiation in relation to TB treatment outcomes will also require future exploration." We hope this response is satisfactory.

Comment \#2

2\. Line 120 - I find the use of \"short-course\" confusing here, since the WHO has guidelines for short- and long-course DR-TB treatment. I would consider rephrasing. The reference \[2\] \"DOTS-Plus and Green Light Committee\" refers to 6-8 months with first-line anti-TB treatment.

Response

Noted, the term "Short course" has been removed and the sentence now reads as follows: "In 2000, WHO recommended the 20-24 month standardized second-line drug (SLDs) regimens for treatment of MDR/RR-TB patients in resource-limited settings". We have also removed the reference \[2\] on the DOTS-Plus and the Green Light Committee.

Comment \#3

3\. Line 134 - requires a reference for \"WHO has recommended shorter regimens\".

Response

Thank you. We have now referenced the 2019 WHO consolidated guidelines on drug-resistant tuberculosis treatment.

Comment \#4

4\. Line 150 - Please clarify what the short course regimen is, in your setting (e.g. shorter, injectable-based, 9-12 month regimen)

Response

Noted, thank you. Now clarified and it reads: "In 2016, the short treatment regimen which is over 9-11 months and injectable based was adopted"

Comment \#4 (Duplication of numbering)

Line 132 - The authors refer to the shorter regimen and Line 152 - authors state that the short regimen has been rolled out in the NTP. Since the paper focuses on the standard long-course RR/MDR-TB regimen (18-24 month), between 2010 - 2015, the authors need to mention why the paper is relevant (since short course has been adopted by the NTP).

Response

The short treatment course was piloted since June 2018 and is made available only in a few districts. Even in districts where short regimen is available, very few patients are started on it due to issues in assessing eligibility. Up to now most districts are still implementing the 18-24 month regimen. The short regimen might have been initiated in less than 5% patients. The study is relevant as it informs on the treatment outcomes with longer regimens and also provides a baseline estimate for tracking the successful outcomes rates with scale up of short regimen in future.

Comment \#5

5\. Line 189 - write out \"MTB/Rif\" the first time it appears in the text; Line 192 - write out \"PTB\" the first time it appears in the text e.g. pulmonary TB (PTB); Line 224 - write out \"PMDT\" the first time it appears in the text; Line 230-233 - write out plus (+) and Lopinavir/Ritonavir and the correct abbreviation LPV/r

Response

Line 189-\"MTB/Rif\" now appears in full the first time it appears in the text

Line 192-"PTB" now appears as "Pulmonary TB" the first time it appears in the text

Line 224-"PMDT\" written in full the first time it appeared in line 149.

Line 230-233- Lopinavir/Ritonavir) (ABC + 3TC + EFV now reflected and LPV/r now reflected

Comment \#6

6\. The authors have introduced selection bias, which is a limitation of the study. The study includes MDR/RR-TB patients who initiated treatment between 2010 and 2015 and continued treatment at either district hospitals or urban polyclinics (Line 237). Those who were referred to primary health facilities were excluded (Line 239). This may contribute to why treatment outcomes are different to what is reported to the WHO by the NTP of Zimbabwe. Those who are referred to primary health facilities are considered more stable, tolerating the regimen, and live close to the PHC. These factors, including distance, have been shown to be associated with treatment outcomes, adherence to treatment and utilization of treatment services. The study population therefore presents patients who were unstable/not tolerating the regimen and/or those who lived \>10km from the health facility. The fact that the study does not include any treatment outcomes for patients referred to primary health facilities is a limitation.

Response

Thank you very much for concurring with the authors that the study had some limitations as referred above. The above Editor concern has been articulated at length as a study limitation and authors acknowledged this quite extensively

Comment \#7

7\. Line 219 - please clarify what constitutes \"stable\". What criteria is used to determine if a patient is stable?

Response

"Stable" is a term used to describe those patients who were able to ingest medication, did not show signs of adverse drug reaction and had all the laboratory investigations within normal limit. This description now appears in line 219

Comment \#8

8\. Line 252 - Please clarify how \"missed doses\" is reported. Is this patient self-report or obtained from clinical data (e.g. dispensed)?

Response

"Missed doses" are determined from patient clinical records specifically from the patient treatment card. As the directly observed treatment is provided, the 'right tick' is made against the particular date in the treatment card by the clinician when drugs are consumed. In case if the patient fails to report for DOT at the health facility, a follow up is done and in the event the patient is not located and misses his drugs for that day, it is marked as missed with 'wrong' tick against that date. We considered all the 'wrong' tick till the date of treatment outcome as 'Missed doses', Later we calculated the percentage of missed doses per total number of days the patient was receiving the treatment.

Comment \#9

9(1) Line 269 - regarding treatment outcomes; (1) authors should refer to the WHO reporting framework and include the definitions of the outcomes.

Response

Noted. "Table of Treatment Outcomes definition" referred as Fig 2

9(2) authors needs to include when the outcome was defined (i.e. how long were patients followed-up for, what is the person-time?), (3) the definition of primary outcome seems unusual - can authors include a reference for this?, (4) since death and LTFU are assigned when the outcome occurs, it is more appropriate to combine death + LTFU in your outcome definition and use Cox Proportional Hazard regression

Response

Patient TB treatment outcomes were defined at 24 months from date of each patients MDR-TB treatment start date until date of their respective outcomes for deaths, LTFUs, treatment failure and "outcome not evaluated". Those classified as LTFU were defined as a patient whose MDR-TB treatment was interrupted for two or more consecutive months for any reason as per WHO guidelines. Those cured or who completed their treatment were categorized as successful treatment outcomes, whereas the others were categorized as unsuccessful treatment outcomes in line with recent meta-analysis studies by Kibret et al and Johston JC et al. We have added this to the data analysis section of our paper

The 473 patients in our study contributed 672.5 person-years. We have added this to the first paragraph of the results section. Thank you for suggesting that we use Cox Proportional Hazards regression. We considered this at length as the most appropriate analysis method, however we finally abandoned it because there were a number of patients who had missing dates on treatment outcomes hence this would lower our sample size.

Comment \#10

10\. Line 280 - 282 - IRB protocol numbers need to be included. Line 283 - \"health and child care\" should be corrected as in Line 282 \"Ministry of Health and Child Care\"

Response

Line 280 - 282 - IRB protocol numbers now included.

Line 283 - \"health and child care\"- Both sentences line 282 and 283 read as "Ministry of Health and Child Care" from original texts

Comment \#11

Line 233 - Guidelines for the use of cotrimoxazole (CPT) should be included in the Methods.

Response

A reference for the guidelines of use of Cotrimoxazole Preventive Therapy is now indicated and the reference section has been updated

Comment \#12

12\. Line 569 - some key variables are missing in Table 2. Examples include resistance pattern (e.g. MDR-TB, RR-TB (mono; isoniazid sensitive) or RR-TB with additional resistance unknown), time on ART, CD4 count, smear microscopy results, weight/BMI (Line 268), EPTB vs. PTB.

Response

Thank you for observing that some key variables are missing in Table 2. All the above are missing data as explained in the section on study limitations

Comment \#13

13\. Line 236 and Table 1 - please clarify if the study includes children? From Table 1 n=24 were \<24 years. It is not clear if this is 18-24 or 0-24? If the latter, then this should be further categorized as children (\<10) or adolescents (10-24) or further as young adolescent (10-14), older adolescent (15-19) and young adult (20-24).

Response

The study does include children. We had collapsed the age groups \<24 years because of small numbers, however we have reverted back to the disaggregation of \<5, 5-14 and 15-24 years in Table 1 but however maintained the combined age group of \<24 years in the multivariate regression analysis table so as to allow for adequate numbers for calculating relative risks and their 95% confidence intervals. We also used the age categories \<24, 25-34, 35-44, 45-54 and 55+ years as these are the standard age groups for reporting TB data to WHO and are also used in several studies to allow for comparisons.

Comment \#14

14\. Table 2 Encountered SAEs - Is this during treatment or at treatment initiation. If the former, then this should be separated out from the characteristics at treatment initiation (Clarify that Table 2 includes clinical characteristics AT treatment initiation). Would be useful to include/mention the most common SAEs reported in the Table (i.e. Table 3?)

Response

Thank you for the point. The encountered SAEs were during treatment and we have rephrased the variable as "Encountered SAE during treatment". Seeing that some patients may have also initiated ART during MDR-TB treatment and that we have the variable on missed treatment dosses in this table, we have instead rephrased the table title as "Clinical characteristics of MDR/RR-TB patients at baseline and/or during treatment among MDR/RR-TB patients initiated on treatment in Zimbabwe, 2010-2015". We hope that this is satisfactory.

Comment \#15

15\. Table 3 Outcomes should add up to 100% - Failed should be 0.9% and not \<1 and LTFU 8.2% (39/473). Therefore, 26.4 + 8.2 + 0.9 + 3.4 = 100%

Response

Many thanks for pointing this out. We have replaced the percentage for those with treatment failure with 0.8% however we note that the percentages for the different end-of-TB treatment outcomes add up to 99.9% due to rounding-off errors. We have specified this as a footnote to the table.

Comment \#16

16\. Table 4 - consider defining a resistance pattern variable - which should encompass the diagnostic test and the DST results.

Response

Thank you for the comment. This information was not available due to missing data on CDST results which the authors highlighted as a study limitation in the discussion section.

Comment \#17

17\. Table 4 -- The current model ignores the time-varying nature of adherence.

Response

This is indeed a valid comment and we ought to have included missed doses as a time dependent variable in our univariate and multivariate-adjusted regression models. However, we did not have data on the specific time points when MDR-TB treatment doses were missed as these were aggregated for each patient by the time they achieved their treatment outcome

Comment \#18

18\. Figure 1 - It would be useful to present outcomes as typically reported by the WHO (e.g. see <https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf> - Page 80)

Response

Thank you for the comment. The term "Unfavourable Outcome" has been further clarified in the text as per WHO reporting system (Death, Treatment failure, LTFU and Not Evaluated)

Reviewer \#1:

I appreciate the work of the Authors to try to define factors associated with unfavourable outcomes in RR and MDR TB in a Country with a very high percentage of HIV co-infected patients.

I suggest the Authors to stress the need for individualized treatment regimens in order to decrease side effects (BMC Infect Dis. 2019 Jun 28;19(1):564. doi: 10.1186/s12879-019-4211-0.) and to cite the need for better treatment compliance (BMC Infect Dis. 2017 Jan 21;17(1):91. doi: 10.1186/s12879-017-2200-8. and Multidiscip Respir Med. 2018 Nov 9;13:41. doi: 10.1186/s40248-018-0154-3. eCollection 2018)

Response

The authors appreciate this valid comment. On study implications, line 409, the authors stresses the need for NTP to adopt shorter treatment regimen for MDR-TB treatment which has been shown to have fewer SAEs. A reference has been added and cited in the reference section as advised

Line 417, the authors stresses the need to ensure that patients do not have missed doses during MDR-TB treatment in order to lessen their risk of having unfavourable outcomes. . A reference has been added and cited in the reference section as advised.

Reviewer \#2:

TITLE -- Consider adding 'Urban Setting' to the title since the population belongs to urban areas and probably a bias to favorable outcome.

Response

Thank you for raising this important point, however the study was not primarily set for the urban population as some district hospitals serve mostly rural populations thus the study population was both urban and rural

Abstract -- appropriate -- consider elaborating the methods.

Response

Thank you for this comment. The methods section of the abstract has been elaborated as advised. The following statement has been added "A generalized linear model with a log-link and binomial distribution or a poisson distribution with robust error variances were used assess factors associated with "unfavorable outcome". The unadjusted and adjusted relative risks were calculated as measure of association. A �value\< 0.05 was considered statistically significant".

Introduction -- Describes the problem in a complete and relevant manner. Aim of the study is well reported.

Response

Thank you, well appreciated

Comment

Method -- Please consider mentioning the type of phenotypic cultures utilized.

Response

Thank you. The type of phenotypic cultures utilized is now indicated as BBLTM MGITTM Mycobacterial Growth Indicator Tubes (Becton Dickinson, Sparks, MD

Comment

Operational definition of treatment outcomes, although standardized as per WHO -- please reiterate here, this can prevent a bit of confusion

Response

Noted, Fig 2 has been added to clarify

Comment

Results -- Now as mentioned by the authors in terms of limitation -- the absence of data on management of SAE, CDST results, CD4 count and comorbidity data. I can suggest certain key data variables which are missing, if available, consider providing them.

BMI, radiological evidence of cavities as they may have direct effect on outcome as well as occupational history and smoking status of the cohort, both of which are strong risk factors for developing TB and unfavorable outcome

Response

We thank you for raising this very valid comment. As already mentioned as study limitations, the data suggested was missing and cannot be included

Comment

It is unfortunate that DST results of fluoroquinolones and second line injectables are not available, both of which are known to be risk factors for adverse outcome, if for the \~53 cases this data can be made available and analysed as a risk factor, it will greatly strengthen your study. It is a strong point for advocating the need of DST.

Response

Thank you for the comment. Of all the second-line injectables and flouroquinolones in use (i.e. kanamycin, Levofloxacin, Moxifloxacin and Cycloserine and Capriomycin alone as an alternative to those intolerant to kanamycin), only 3 patients were resistant to any one of the above hence we could not include this variable in the univariate and multivariate regression analysis because of the small numbers.

Comment

Data for Time to unfavourable outcome -- is a strong variable that can help us in understanding the severity of the cohort population and help in future intervention. Did any SAE led to unfavourable outcome? The individuals who died or lost to follow up -- were recorded to be failing the regimen?

Response

Thank you for raising this very important observation. In our univariate and multivariate regression encountering an SAE was not significant predictor of an unfavourable outcome as shown in Table 5. Also, due to deficiencies in our data and this being a retrospective study, we failed to assess the cause-effect relationship of SAEs and unfavourable outcome

Comment

Details of ART initiation is not provided neither the status of ART success or failing is analysed.

Response

Thank you. Unfortunately data on virological, immunological or clinical failure of patients initiated on ART were not available in the DR-TB registers hence required matching patient names to the ART registers given that there was no unique identifier linking the ART and MDR-TB programmes. However we do acknowledge the importance of this data and is something that was worth exploring and should be explored in future studies.

Comment

Discussion:

The authors have done proper analysis of their results, aptly described the limitation and strengths of the study as well as compared the results with similar studies.

Response

Thank you, comment well appreciated

Comment

Please elaborate on the reason for 180 people with no recorded time for culture conversion -- they failed to culture convert or some of them died before or some could not give the sample

Response

Thank you for asking us to elaborate. These patients either did not have their samples examined because of contamination, spillages or did not have results (CDST) sent back to the health facility and the reasons are well explained under the section on study implications where the authors mentioned that the high proportion of patients who did not have CDST results during their treatment is cause for concern as this is essential in monitoring bacteriological response to treatment. A recent study from Zimbabwe showed leakages in receipt of sputum samples at NRLs, culture contamination among received sputum specimens leading to a reduced proportion of samples with CDST results and this was mentioned in the relevant section. The authors concluded by stressing that this CDST system will require improvements including feedback of CDST results to facilities in order to inform patient management.

Comment

How many patient had their sputum culture status reverted back to positive

Response

Thank you for this question. None had their sputum culture status reverted back to positive

Comment

Interestingly, \~14% of the study cohort was initiated on ATT beyond 30 days of RRTB diagnosis, was not found to affect the outcome. You may consider highlighting that delay in initiation for SLD.

Response

Thank you for pointing this out. We have mentioned the following in the discussion section: "Last, a significant number of patients delayed initiation of MDR-TB treatment by more than 30 days after RR-TB diagnosis. Whilst this was not associated with having an unfavourable outcome, this has got dire consequences at an individual level towards disease progression and at a population-level towards MDR-TB transmission in the community."

Reviewer \#3:

Comment \#1

Background is unclear and does not adequately contextualize the aims of the manuscript.

Response

Thank you for the comment. This study aimed at assessing the profile, treatment outcomes and factors associated with unfavourable treatment outcomes among patients initiated on MDR/RR-TB treatment. In view of this we started by highlighting the global burden of MDR/RR-TB and also mentioned the WHO MDR/RR-TB treatment targets as a benchmark to assess our poor performance in this regard. We further summarised some of the literature of risk factors associated with poor MDR-TB treatment outcomes before we highlighted the paucity of data on treatment outcome determinants in our setting. This is of interest to the Zimbabwe NTP in order to have tailored interventions aimed at improving our overall MDR-TB treatment success rate. We do appreciate your comment and would like your further guidance on specific sections that require rewriting in order to make the introduction more appealing.

Comment \#2

Methods lack clarity on how outcomes were defined, time-points at which outcomes were assessed by, measurement of covariates like adverse events is not suitable, inferential analytic techniques are also questionable.

Response

Thank you for this comment. We have addressed your comment on outcome definitions and time-points for assessment of these outcomes are addressed in the data entry and analysis section in line with other reviewers comments. As for inferential analytical techniques, we would have preferred to use Cox Hazards regression analysis to generate hazard ratios, however due to a large proportion of missing data on time of outcomes, we resorted to generating relative risk instead. Also, as our outcome of interest in this manuscript is 'unfavourable outcome', which includes 'death', LTFU, failure and 'not evaluated' we considered binomial regression. If at all we were modelling for death or LTFU than the Cox Hazard regression would have been the only option.

Comment \#3

Results are sparse and could be described in greater detail.

Response

Thank you. In our analysis, we generated tables that responded to each of our set specific objectives and were hesitant to delve into greater detail for fear of digressing from our set objectives. However, we would appreciate if you can specify particular detail which would be of interest to the readers of our paper and is also aligned with our study objectives.

Comment \#4

It is not very clear how background, aims, methods, results tie into the discussion and conclusions.

Response

Thank you for the comment. We are however surprised that this is the case as your comment is contradictory to the other 2 reviewers. In writing the paper we carefully attempted to logically align our discussion to the results presented which in turn were informed by the background, aims and methods of the study. We hope this is understandable with you

Comments:

1\. Keywords

a\. Repeated (full-text and abbreviations used for the same word)

Response

We have gone through the whole manuscript and ensured that full-text and abbreviations are reported together only once, following which only abbreviations are mentioned were necessary.

a\) Background

Comment

Tuberculosis to be written out in full before abbreviated

Response

Thank you. Tuberculosis now written out in full the first time it is used before being abbreviated

Comment

Incorrect order of abbreviations for RR/MDR-TB. Authors write this out in full starting with MDR-TB.

Response

Thank you for this. We appreciate that MDR/RR-TB can be written as RR/MDR-TB however after careful consideration, the study investigator team opted to align with MDR/RR-TB which is used in the WHO global TB reports and guidelines. We hope this is understandable.

Comment

Please rephrase last sentence. This is unclear

Response

Thank you for the comment. The last sentence on the background now rephrased and reads "The profile, management, and factors associated with unfavourable treatment outcomes of MDR/RR TB have not been systematically evaluated in Zimbabwe".

Comment

b\) Design

1\) Please provide more detail regarding the methods you employ to assess treatment outcomes and risk factors for such outcomes. Study sites, participants, data collected, analytic methods used, definition of outcomes assessed, time point outcomes were assessed by etc.

Response

Study sites were all district hospitals and urban polyclinics in Zimbabwe. The study participants were all MDR/RR-TB patients initiated on treatment between 2010-2015 under the Zimbabwe NTP and continued their treatment in the above mentioned health facilities. This information is stated in the section on "Study Population". We have further on added the total number of district hospitals and urban polyclinics which totalled eighty-two under study design. As per your earlier request we have specified the time point outcomes assessed in the "Data entry and analysis" section.

2\) How were participants selected for the final analysis?

Response

We thank you for asking us to explain. Of the total 935 MDR/RR-TB patients initiated on treated during study reference period , the 473 (51%) of patients who met the study inclusion criteria of those started on MDR/RR-TB treatment and continued their 20-24 month treatment at district and urban polyclinics were all included in the study

Comment

c\) Results

i\. How was missing MDR-TB treatment doses defined? Please add to methods.

Response

Thank you. Percentage of missed doses is defined as percentage of the number of days with missed doses divided by the total number of days a patient was on treatment up until date of outcome. This has been added to methods section

Comments

ii\. Did outcomes differ between RR-TB and MDR-TB?

Response

Thank you for this valid comment. As shown in Table 5, based on the individual analysis of isoniazid, streptomycin and ethambutol resistant patterns at baseline, there were no differences in outcomes between RR-TB and MDR-TB patients. Furthermore, it is difficult to conclusively distinguish between RR-TB and MDR-TB patients as the majority of patients did not have DST results recorded or at least for all second-line TB drugs..

Comment

iii\. How were covariates selected to be included in the main effects model? Please add to methods.

Response

Thank you for the comment. All covariates with a p\<0.25 and those that are biologically plausible predictors of unfavourable outcomes were added to the multivariate regression model. This is mentioned in the "Data entry and analysis" section.

Comment

iv\. Why was 'not evaluated' outcome considered unfavourable?

Response

Those "not evaluated" were included in those with unfavourable outcomes as stated in the "Data entry and analysis" section in line with recent meta-analysis studies by Kibret et al and Johston JC et al. The WHO in its annual TB report, considers 'not evaluated' as 'unfavourable' or 'unsuccessful' outcome

Comment

d)Conclusion

v\. Stating that outcomes were poor coupled with high occurrence of adverse events make it seems like this was a significant risk factor -- but it wasn't?

Response

Thank you for the comment. Whilst we acknowledge that adverse events were not a significant risk factor, in paragraph 6 of the discussion section we only highlight that the high proportion of SAEs in this patient cohort (i.e. one in four patients) is a cause for concern and do not insinuate that this is a risk factor for unfavourable outcomes. We further advocate for more standardized recording and reporting of SAEs for better tracking by the NTP and also advocate for wider adoption of the shorter MDR-TB treatment regimen

Comment

vi\. Conclusions and recommendations are based on adverse events; however this is not mentioned as a significant predictor in the results. Therefore, how are these conclusions relevant to your findings?

Response

Thank you. Please refer to the earlier response above.

2\. Introduction -Comment

i\. Capitalize 'tuberculosis' line 112

Response

"T" Now in capital letters

Comment

ii\. Don't start a sentence with an abbreviation -- line 114 and other places within the text

Response

Line 114 and 118 corrected

Comment

Insert "The" before World Health Organisation

Response

The World Health Organization' -- line 116

"The" Inserted

Comment

iii\. Line 120 -- is this reference from 2000?

Response

Thank you. Yes, we can confirm that the reference is from 2000

Comment

iv\. Line 128-129 -- please clarify what the second part of this sentence means

Response

The authors of the systematic review paper stated that studies included in the review were largely from countries with low HIV coinfection. They then recommended for systematic assessment of treatment outcomes in high HIV coinfection countries of sub-Saharan Africa

Comment

v\. Could you comment on the incidence of ADRs on second-line TB treatment? Line 130-134

Response

Thank you for raising this comment. We could not generate incidence rate of ADRs as we did not have data on time of their occurrence.

Comment

vi\. Could you comment on eligibility for newer shorter regimens? Line 130-134

Response

Thank you for asking us to comment. Eligibility for newer shorter regimens is when there is no risk or confirmed resistance to any second line medicines or any medicine used in the shorter treatment regimen

Comment

vii\. However, unsure of commenting on newer short course regimens -- what does this have to do with assessing treatment outcomes in your traditional-long course cohort? Shorter regimens may be more pertinent in your discussion.

Response

Our apologies as we do not clearly understand your comment. If we understand well, you suggest that we mention the importance of the newer short course regimen as an alternative to the traditional long course regimen. We have touched on this in paragraph 10 of the discussion section were we suggest that the NTP should adopt wider scale up of the shorter treatment regimen which has fewer SAEs although treatment outcomes are comparable to the long MDR-TB treatment regimen.

3\. Methods

Comment

viii\. Could a figure describing the general setting be included to better understand the public healthcare setting? And thereafter selection process

Response

Thank you for suggesting this. We have attempted to present this information graphically but have concluded that the text description mentioned in the General setting and the description of diagnosis and treatment of MDR/RR-TB gives an overall description of Zimbabwe's public health setting in the context of the National TB Programme. We are happy to clarify any specific sections that are unclear to you.

Comment

ix\. Line 212-213 -- WHO recommended DOTS-plus during the study period? Or as above in 2000?

Response

In 2000, Tense changed to reflect "Was" instead of "be"

Comment

x\. Line 237 -238 please rephrase

Response

Rephrased as per reviewer 3 comments, sentence now short and more precise

Comment

xi\. Would patients referred for DOTS-plus who were then excluded from the analysis be systematically different to those who were included?

Response

Yes we do acknowledge this possibility given that the treatment success rate for our study population was better than that reported by the NTP for all patients due to their high proportion of unevaluated patients. Furthermore in rural settings health facilities are less accessible due to long distances from households and there is less specialized care in rural facilities. We have stated this as a limitation in the discussion section.

Comment

xii\. Line 243 -- consistency with capitalization

Response

We have noted this and addressed it accordingly.

Comment

xiii\. Data quality between sites could differ? Were there any systematic differences between quality (missing data) etc. between sites?

Response

Thank you for this comment, however there were no systematic differences between sites in terms of data quality. Missing data was across all sites because the tools used by all sites were the same and no data was collected on those variables. Also all the sites sent their samples to the same reference laboratory which did not give results back on CDST. Furthermore 10%of the data was subjected to quality assurance and originally missing data was completed before final data entry.

Comment

xiv\. Since the primary outcome of interest is death and LTFU which can occur any time from treatment initiation -- would you consider using a Cox Hazard Model to determine hazard ratio estimates of 'unfavourable outcomes'? Considering time to outcome may be an important factor which could be affected differently by different risk factors. Furthermore, was LTFU and death separated and did risk factors differ by these outcomes? Lastly, what is the motivation for including 'not evaluated' as an 'unfavourable outcome'?

Response

As mentioned above we could not perform Cox Hazard regression analysis due to the high proportion of missingness on time to event data. We also reserved further comparisons on any differences between predictors of mortality and LTFU for another paper as we felt this was too much information for one paper. We hope reviewers understand our position.

Comment

xv\. Please include a time-point at which outcomes were assessed by. Did everyone have a minimum follow-up etc.?

Response

Yes, since this was a retrospective cohort study based on routinely collected programme data, all patients were allowed a follow-up period for their potential 20-24 month MDR-TB treatment duration.

Comment

3Results

xvi\. Line 287 -- punctuation

Response

Thank you, we consider the punctuation used to be fine and appropriate as "Ethics approval was granted by The Union Ethics Advisory Group of the International Union against Tuberculosis and Lung Diseases, Paris, France, IRB number EAG 53/18 and the Medical Research Council of Zimbabwe (MRCZ), IRB number MRCZ/A/2331"

Comment

xvii\. Measurement of adverse events seems to have been recorded throughout treatment for respective patients. If so, this cannot be included as a potential risk factor in the predictive analysis as results would be prone to systematic bias. Those who remain in care long enough to develop and record ADRs will be different from those who do not. If ADRs are to be included, this should be recorded within a pre-defined period around baseline i.e., within 14 days after starting treatment for example. Thereafter, the analysis should be rerun.

Response

Thank you for the valid comment. We have removed SAEs from the multivariate regression model.

Comment

xviii\. Table 4 -- stepwise approach to model selection given in methods -- but no p-values shown in table?

Response

Thank you for raising this comment. We did not include p-values as they would be redundant given that the reported univariate and multivariate-adjusted relative risks with 95% confidence intervals are more informative. When the 95%CI doesn't cross the null value, then the factor is significant.

Comment

xix\. How would the reader interpret significant risk factors for variables with categories that were 'not recorded'? i.e., streptomycin DST pattern, Ethambutol DST pattern? Isoniazid DST pattern, missed doses?

Response

We appreciate your comment, however the interpretation for unrecorded data will be largely not make programmatic interpretation especially for the "missed doses" variable. We however included all the patients with unrecorded data in the univariate and multivariate-adjusted regression models for the selected variables since excluding them will greatly diminish the eligible sample given the large amount of missing data as is often the case with routinely collected programme data.

Comment

3\. Discussion

i\. Line 316-324 -- please rephrase language used here.

Response

Thank you. Rephrased to make the statement clearer as" The proportion with an unfavourable treatment outcome (death, Treatment failure, LTFU and Not evaluated) increased annually from 0% in 2010 to 45% in 2015 (Figure-1).

Factors associated with an unfavourable outcome among patients on MDR-TB treatment are shown in Table 4.

Those who were HIV-positive and ART-naive (ARR=2.83; 95% CI: 1.44-5.57) and those who missed \>10% of their MDR-TB treatment dosses (ARR=2.41; 95% CI: 1.59-3.67) were more likely to have an unfavourable treatment outcome

Comment

ii\. Line 325-326: what was the breakdown of patients across sites? Did some sites have a disproportionally higher number of patients?

Response

Thank you for the comment. Fifty-two out of sixty-three district hospitals that notified an MDR/RR TB patient during 2010-2015 contributed different numbers of the patients included in the study who were not refered to rural health centres. Thirty polyclinics from the two metro-politan provinces also contributed varied numbers but less patients per site as compared to what the district hospitals notified.

Across sites, yes the numbers were different depending on various factors as per the inclusion criteria described in the study design.

Comment

iii\. Please consider the use of language in the strength and limitations sections of the discussion.

Response

The language used is deemed appropriate for a scientific paper as it arranges the strengths and limitations as first, second, third etc thus allowing the reader to follow the sequence of the issues highlighted.

Comment

iv\. Line 328 -- how were operational challenges assessed in this analysis?

Response

Since this study was based on a retrospective review of routine patient records. Therefore we did not conduct a process evaluation which would have been useful in determining operational challenges encountered in treatment and management of patients on MDR-TB treatment

Comment

v\. Line 336 and 337 seems to be in contradiction to line 325-326

Response

Thank you for the observation, we however think there is no contradiction as a district has both urban and rural population. The participants included in our study were predominantly from the urban part of the district yet those that were excluded were predominantly from the rural part of the same district. It is not necessarily correct to assume that districts have only rural population

Comment

vi\. Line 343-344 -- if these changes were assessed during treatment, I'm not sure they would be suitable in your predictive analysis for the reasons of systematic bias as mentioned above

Response

Thank you. Comorbidities were determined during eliciting patient history at MDR-TB treatment initiation. We have revisited line 343-344 and specified this.

Comment

vii\. Line 357-359 -- could you comment on time on ART

Response

Thank you. unfortunately data on ART initiation start dates were not available in the DR-TB registers hence we could not assess timing of ART in relation to MDR-TB treatment commencement. We have added this as a limitation to paragraph of the discussion section.

Comment

viii\. Line 363 -- still unsure of exactly how missed doses was defined? Please could this be clarified in the methods.

Response

Thank you, Missed doses are clearly defined under Methods (Operational Definitions) Line 255 as percentage of the number of days with missed doses divided by the total number of days a patient was on treatment up until date of outcome.

Comment

ix\. Line 387 -- at what time-point was cured/completed outcomes assessed? Was this by 24 months on treatment? As mentioned above -- the time point at which outcomes were assessed is not clear here.

Response

Thank you. Time point of cured/completed outcomes was assessed at the end of treatment duration.

Comment

x\. Line 411 -- could you provide a measure of time between missed doses in the results section.

Response

Thank you. The following statement has been added to the results section under implications of study results: " If a patient consecutively misses doses of two months or more, the patient is considered lost to follow-up and will restart treatment upon return".

Comment

xi\. Line 419-423 -- it is still not clear how findings presented here link to the conclusions presented.

Response

Our conclusions were linked to our major study findings which are as follows: 1) the MDR-TB treatment success rate was lower than the WHO treatment success target 2) treatment outcomes were better among those on ART whilst 3) missed doses of more than 10% were associated with poor outcomes. In addition, we have also made mention of the high occurrence of SAEs

We thank Reviewer 1, 2 and 3 including the Editor for a thorough review and hope we have satisfactorily addressed all the grey areas. We are more than pleased to attend to any further comment that may require a follow-up response

###### 

Submitted filename: RM Authors Response Letter.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0230848.r003

Decision Letter 1

Evans

Denise

Academic Editor

© 2020 Denise Evans

2020

Denise Evans

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

12 Dec 2019

PONE-D-19-16150R1

Treatment outcomes of Multi drug resistant and Rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

PLOS ONE

Dear Mr Matambo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jan 26 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Denise Evans, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: TITLE -- Consider adding 'Urban Setting' to the title since the population belongs to

urban areas and probably a bias to favorable outcome.

Response

Thank you for raising this important point, however the study was not primarily set for

the urban population as some district hospitals serve mostly rural populations thus the

study population was both urban and rural

Reviewer's Response: Author's response acceptable.

Abstract -- appropriate -- consider elaborating the methods.

Response

Thank you for this comment. The methods section of the abstract has been elaborated

as advised. The following statement has been added "A generalized linear model with

a log-link and binomial distribution or a poisson distribution with robust error variances

were used assess factors associated with "unfavorable outcome". The unadjusted and

adjusted relative risks were calculated as measure of association. A value\< 0.05 was

considered statistically significant".

Reviewer's Response: Author's response acceptable.

Introduction -- Describes the problem in a complete and relevant manner. Aim of the

study is well reported.

Response

Thank you, well appreciated

Comment

Method -- Please consider mentioning the type of phenotypic cultures utilized.

Response

Thank you. The type of phenotypic cultures utilized is now indicated as BBLTM

MGITTM Mycobacterial Growth Indicator Tubes (Becton Dickinson, Sparks, MD

Reviewer's Response: Addition of information is appreciated.

Comment

Operational definition of treatment outcomes, although standardized as per WHO --

please reiterate here, this can prevent a bit of confusion

Response

Noted, Fig 2 has been added to clarify

Reviewer's Response: Appropriate action taken.

Comment

Results -- Now as mentioned by the authors in terms of limitation -- the absence of data

on management of SAE, CDST results, CD4 count and comorbidity data. I can suggest

certain key data variables which are missing, if available, consider providing them.

BMI, radiological evidence of cavities as they may have direct effect on outcome as

well as occupational history and smoking status of the cohort, both of which are strong

risk factors for developing TB and unfavorable outcome

Response

We thank you for raising this very valid comment. As already mentioned as study

limitations, the data suggested was missing and cannot be included

Reviewer's Response: Consider adding -- lack of radiological data in the heading of limitation.

Comment

It is unfortunate that DST results of fluoroquinolones and second line injectables are

not available, both of which are known to be risk factors for adverse outcome, if for the

\~53 cases this data can be made available and analysed as a risk factor, it will greatly

strengthen your study. It is a strong point for advocating the need of DST.

Response

Thank you for the comment. Of all the second-line injectables and flouroquinolones in

use (i.e. kanamycin, Levofloxacin, Moxifloxacin and Cycloserine and Capriomycin

alone as an alternative to those intolerant to kanamycin), only 3 patients were resistant

to any one of the above hence we could not include this variable in the univariate and

multivariate regression analysis because of the small numbers.

Reviewer's Response: Author's response accepted.

Comment

Data for Time to unfavourable outcome -- is a strong variable that can help us in

understanding the severity of the cohort population and help in future intervention. Did

any SAE led to unfavourable outcome? The individuals who died or lost to follow up --

were recorded to be failing the regimen?

Response

Thank you for raising this very important observation. In our univariate and multivariate

regression encountering an SAE was not significant predictor of an unfavourable

outcome as shown in Table 5. Also, due to deficiencies in our data and this being a

retrospective study, we failed to assess the cause-effect relationship of SAEs and

unfavourable outcome

Reviewer's Repsone: Clarification needed for patients -- Lost to follow up or died- were the failing on the current regimen.

Comment

Details of ART initiation is not provided neither the status of ART success or failing is

analysed.

Response

Thank you. Unfortunately data on virological, immunological or clinical failure of

patients initiated on ART were not available in the DR-TB registers hence required

matching patient names to the ART registers given that there was no unique identifier

linking the ART and MDR-TB programmes. However we do acknowledge the

importance of this data and is something that was worth exploring and should be

explored in future studies.

Reviewer's Repsonse: Please consider mentioning this shortcoming in the Discussion.

Comment

Discussion:

The authors have done proper analysis of their results, aptly described the limitation

and strengths of the study as well as compared the results with similar studies.

Response

Thank you, comment well appreciated

Reviewer's Response: No further action needed

Comment

Please elaborate on the reason for 180 people with no recorded time for culture

conversion -- they failed to culture convert or some of them died before or some could

not give the sample

Response

Thank you for asking us to elaborate. These patients either did not have their samples

examined because of contamination, spillages or did not have results (CDST) sent

back to the health facility and the reasons are well explained under the section on

study implications where the authors mentioned that the high proportion of patients

who did not have CDST results during their treatment is cause for concern as this is

essential in monitoring bacteriological response to treatment. A recent study from

Zimbabwe showed leakages in receipt of sputum samples at NRLs, culture

contamination among received sputum specimens leading to a reduced proportion of

samples with CDST results and this was mentioned in the relevant section. The

authors concluded by stressing that this CDST system will require improvements

including feedback of CDST results to facilities in order to inform patient management.

Reviewer's Response: Satisfactory reply received

Comment

How many patient had their sputum culture status reverted back to positive

Response

Thank you for this question. None had their sputum culture status reverted back to

Positive

Reviewer's Response: No further action needed

Comment

Interestingly, \~14% of the study cohort was initiated on ATT beyond 30 days of RRTB

diagnosis, was not found to affect the outcome. You may consider highlighting that

delay in initiation for SLD.

Response

Thank you for pointing this out. We have mentioned the following in the discussion

section: "Last, a significant number of patients delayed initiation of MDR-TB treatment

by more than 30 days after RR-TB diagnosis. Whilst this was not associated with

having an unfavourable outcome, this has got dire consequences at an individual level

towards disease progression and at a population-level towards MDR-TB transmission

in the community."

Reviewer's Response: No further action required

Conclusion: Most of the queries are answered with satisfactory responses. However, the data collection is deficient in terms of several key indicators and weakens the quality of study. This is an inherent weakness of a retrospective study which derives data from NTP. I do appreciate the hard work of the authors in the resource limited setting and understand the difficulties faced. The study can be accepted with minor correction.

Reviewer \#3: 1. A language editor is strongly recommended. Acceptance of this manuscript should at the very least be contingent on this.

2\. Have the authors looked into the rates and risk factors of unfavorable outcomes separately? i.e. LTFU vs. all-cause mortality vs. unreported etc.? Risk factors may differ across these outcomes and a stratified analysis may add more granularity to this paper (authors should consider at least having these separated outcomes in supplementary tables).

3\. Would the 'not evaluated' outcome include those patients who were still alive and in care by 24 months who had not completed treatment? These patients could be different to those who have met the definition for LTFU, which speaks to the point above.

4\. Gender breakdown listed in abstract is different from Results section. Keeping the reference category the same may make the manuscript easier to read.

5\. Missing \>10% of treatment doses seems to be ascertained throughout treatment and not a once off measurement at baseline? If this is the case, then this cannot be used as a predictor of unfavorable outcome. "Percentage of missed doses: percentage of the number of days with missed doses divided by the total number of days a patient was on treatment up until date of outcome."

6\. "study findings were reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines." This should be included in the methods and not discussion."

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewers

Rebuttal Letter

PLOS ONE

The Editor in Chief

23 December 2019

REF: PONE-D-19-16150: Treatment outcomes of Multi drug resistant and Rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

Dear Editor

Thank you very much for reviewer comments and suggestions during second round review of our above named manuscript. We have carefully read through the reviews and revised our paper accordingly. We feel that the paper is much improved as a result of this review process and thank you for taking it to this stage. We have responded point by point to the comments and suggestions of the reviewers.

We would like to submit the revised version of the manuscript with highlights (R2- track) and the revised and clean version of the manuscript (R2-Clean). The line numbers in the response to reviewer comments corresponds to the line numbers in the revised version with track changes.

Sincerely

R. Matambo (Corresponding Author)

 

Reviewer-1

Comment 1: Consider adding -- lack of radiological data in the heading of limitation.

Author Response

Thank you for your suggestion. We have added the statement under study limitations and now the paragraph reads as follows: "Second, there were missing data on key variables which include CDST results, socioeconomic status, WHO clinical staging, CD4 cell count, timing of ART in relation to MDR-TB treatment commencement, nutritional status, MDR-TB drug regimens and their dosages, data on virological, immunological or clinical failure of patients initiated on ART and radiological findings of TB lesions -- all which are important factors which may be related to MDR-TB treatment outcomes". Line 380

Comment 2: Clarification needed for patients -- Lost to follow up or died- were the failing on the current regimen.

Author Response

Thank you for raising this important query.

As this was a retrospective study, we don't have data to safely conclude whether these patients were failing on the current regimen. Of the 164 patients who died or were LTFU, the majority 112 (68.3%) had no culture conversion result recorded. Of the remaining 52 (31.7%), 48 (94.2%) had culture conversion within 6 months of initiating MDR-TB treatment. Thus, we have not tried to interpret these findings. However, we acknowledge this as a deficiency of the current study.

Comment 3: Details of ART initiation is not provided neither the status of ART success or failing is analysed. Please consider mentioning this shortcoming in the Discussion.

Author Response

Thank you for suggesting that we mention in the discussion section about the un-availability of data on virological, immunological or clinical failure of patients initiated on ART. This has now been mentioned in line 370-371

Comment 4: "study findings were reported in accordance with strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines." This should be included in the methods and not discussion."

Author Response

Thank you for such valid suggestion. We have since incorporated the changes as advised. Line 287-288

Comment 5: A language editor is strongly recommended. Acceptance of this manuscript should at the very least be contingent on this.

Author Response:

Thank you for this suggestion. We have engaged a well experienced scientific editor who has gone through the manuscript and made grammatical changes to the manuscript. The grammatical changes have been made throughout the manuscript.

 

Reviewer 2:

Comment: Have the authors looked into the rates and risk factors of unfavorable outcomes separately? i.e. LTFU vs. all-cause mortality vs. unreported etc.? Risk factors may differ across these outcomes and a stratified analysis may add more granularity to this paper (authors should consider at least having these separated outcomes in supplementary tables).

Author Response:

Thank you for the comment. You raise a very valid point. However, we have another paper in which we had more granular analysis on rates and risk factors of specific unfavorable outcomes (LTFU and death) which if included in this paper would result in duplication. We hope that this is acceptable with the reviewer and the editor if this further analysis is not included in this manuscript.

Comment 2: Would the 'not evaluated' outcome include those patients who were still alive and in care by 24 months who had not completed treatment? These patients could /be different to those who have met the definition for LTFU, which speaks to the point above.

Response: Thank you for the comment. None of the patients in this cohort were still on the treatment at the time of censoring date. Thus, we have not considered anyone still on treatment as 'not evaluated'. Within the TB programme in Zimbabwe, MDR/RR-TB patients who would have completed their MDR-TB treatment with 1) a negative bacteriological confirmation result are considered cured whilst 2) those without bacteriological confirmation are classified as treatment completed. In response to your question above, only 3/33 (9.1%) were LTFU after being on treatment for 24 months. This implies that they were LTFU before completing their extended treatment duration which was a result of having missed treatment for a duration(s) not exceeding 2 months.

Comment 3: Gender breakdown listed in abstract is different from Results section. Keeping the reference category the same may make the manuscript easier to read.

Author Response:

We agree with your comment. We have therefore changed the narrative in the results section to match the reference category in the abstract i.e. "....230 (49%) were males". Line 324-325

Comment 4: Missing \>10% of treatment doses seems to be ascertained throughout treatment and not a once off measurement at baseline? If this is the case, then this cannot be used as a predictor of unfavorable outcome. "Percentage of missed doses: percentage of the number of days with missed doses divided by the total number of days a patient was on treatment up until date of outcome."

Author Response:

Thank you for highlighting the deficiency of this variable. We acknowledge that this cant be used as a predictor. Hence, we have removed variable on missed doses from our univariate and multivariate regression model. We have also removed narrative in the abstract, results section and discussion section with reference to this predictor. Lines 111-112; 349-350; 362; 406-409; Table 5.

Comment 5: "study findings were reported in accordance with strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines." This should be included in the methods and not discussion."

Author Response

Thank you for such valid suggestion. We have since incorporated the changes as advised. Changes made in line number 370-371

We thank you for your esteemed review of our manuscript and hope that we have responded satisfactorily. Please do not hesitate to contact us for further clarification as your reviews enriches our manuscript.
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Reviewer \#1: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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